

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 June 2006 (22.06.2006)

PCT

(10) International Publication Number
WO 2006/064339 A1

(51) International Patent Classification:

A61K 31/437 (2006.01) A61P 1/04 (2006.01)
C07D 471/04 (2006.01)Pfizer Japan Inc., Shinjuku Bunka Quint Bldg., 3-22-7,
Yoyogi, Shibuya-ku, Tokyo 151-8589 (JP).

(21) International Application Number:

PCT/IB2005/003758

(74) Agents: FULLER, Grover, F., Jr. et al.; c/o Drouin,
Stéphane, Pfizer Global Research and Development,
Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(22) International Filing Date:

7 December 2005 (07.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/636,963 17 December 2004 (17.12.2004) US
60/695,772 29 June 2005 (29.06.2005) US(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.(71) Applicant (for JP only): PFIZER JAPAN INC. [JP/JP];
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku,
Tokyo 151-8589 (JP).(71) Applicant (for all designated States except JP, US):
PFIZER INC. [US/US]; 235 East 42nd Street, New York,
NY 10017 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): JINNO, Madoka
[JP/JP]; Pfizer Japan Inc., Shinjuku Bunka Quint Bldg.,
3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589 (JP).
SHIMOKAWA, Hirohisa [JP/JP]; Pfizer Japan Inc.,
Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku,
Tokyo 151-8589 (JP). YAMAGISHI, Tatsuya [JP/JP];(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CHROMANE DERIVATIVES USEFUL AS ACID PUMP ANTAGONISTS



(I)

(57) Abstract: This invention relates to compounds of the formula (I): or
a pharmaceutically acceptable salt thereof, wherein: R¹, R², R³, R⁴, R⁵, R⁶,
R⁷, R⁸ A and B are each as described herein or a pharmaceutically accept-
able salt, and compositions containing such compounds and the method of
treatment and the use, comprising such compounds for the treatment
of a condition mediated by acid pump antagonistic activity such as, but
not limited to, as gastrointestinal disease, gastroesophageal disease, gas-
troesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duode-
nal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori,
dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive
reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dys-
phagia, hypersalivation, airway disorders or asthma.

CHROMANE DERIVATIVES USEFUL AS ACID PUMP ANTAGONISTS

Background of the Invention

This invention relates to chromane derivatives. These compounds have selective acid pump inhibitory activity. The present invention also relates to a pharmaceutical composition, method of treatment and use, comprising the above derivatives for the treatment of disease conditions mediated by acid pump modulating activity; in particular acid pump inhibitory activity.

It has been well established that proton pump inhibitors (PPIs) are prodrugs that undergo an acid-catalyzed chemical rearrangement that permits them to inhibit H^+/K^+ -ATPase by covalently binding to its Cystein residues (Sachs, G. et. al., *Digestive Diseases and Sciences*, 1995, 40, 3S-23S; Sachs et. al., *Annu Rev Pharmacol Toxicol*, 1995, 35, 277-305.). However, unlike PPIs, acid pump antagonists inhibit acid secretion via reversible potassium-competitive inhibition of H^+/K^+ -ATPase. SCH28080 is one of such reversible inhibitors and has been studied extensively. Other newer agents (revaprazan, soraprazan, AZD-0865 and CS-526) have entered in clinical trials confirming their efficacy in human (Pope, A.; Parsons, M., *Trends in Pharmacological Sciences*, 1993, 14, 323-5; Vakil, N., *Alimentary Pharmacology and Therapeutics*, 2004, 19, 1041-1049). In general, acid pump antagonists are found to be useful for the treatment of a variety of diseases, including gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, non-steroidal anti-inflammatory drug (NSAID)-induced ulcers, gastritis, infection of *Helicobacter pylori*, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma (hereinafter, referred as "APA Diseases", Kiljander, Toni O, *American Journal of Medicine*, 2003, 115 (Suppl. 3A), 65S-71S.).


WO99/55706 and WO04/046144 disclose compounds reported to be acid pump antagonists. They refer to certain compounds having imidazo[1,2-a]pyridine structure.

There is a need to provide new acid pump antagonists that are good drug candidates and address unmet needs by PPIs for treating diseases. In particular, preferred compounds should bind potently to the acid pump whilst showing little affinity for other receptors and show functional activity as inhibitors of acid-secretion in stomach. They should be well absorbed from the gastrointestinal tract, be metabolically stable and possess favorable pharmacokinetic properties. They should be non-toxic. Furthermore, the ideal drug candidate will exist in a physical form that is stable, non-hygroscopic and easily formulated.

Summary of the Invention

In this invention, it has now been found out that the new class of compounds having a chromane moiety show acid pump inhibitory activity and favorable properties as drug candidates, and thus are useful for the treatment of disease conditions mediated by acid pump inhibitory activity such as APA Diseases.

The present invention provides a compound of the following formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

-A-B- represents -O-CH₂-, -S-CH₂-, -CH₂-O- or -CH₂-S-;

R¹ represents a C₁-C₆ alkyl group being unsubstituted or substituted with 1 to 2 substituents

5 independently selected from the group consisting of a hydroxy group, a moiety convertible in vivo into a hydroxy group and a C₁-C₆ alkoxy group;

R² represents a C₁-C₆ alkyl group;

R³ represents a C₁-C₆ alkyl group, C₃-C₇ cycloalkyl group or C₃-C₇ cycloalkyl C₁-C₆ alkyl group;

R⁴ represents a C₁-C₆ alkyl group being unsubstituted or substituted with 1 to 3 substituents

10 independently selected from the group consisting of a halogen atom, a hydroxy group, a moiety convertible in vivo into a hydroxy group and a C₁-C₆ alkoxy group; and

R⁵, R⁶, R⁷ and R⁸ independently represent a hydrogen atom, a halogen atom or a C₁-C₆ alkyl group.

Also, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, together with a

15 pharmaceutically acceptable carrier for said compound.

Also, the present invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, further comprising other pharmacologically active agent(s).

Also, the present invention provides a method of treatment of a condition mediated by acid pump modulating activity, in a mammalian subject, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein.

Examples of conditions mediated by acid pump modulating activity include, but are not limited to, APA Diseases.

25 Further, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, for the manufacture of a medicament for the treatment of a condition mediated by acid pump inhibitory activity.

Preferably, the present invention also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, for the manufacture of a medicament

30 for the treatment of diseases selected from APA Diseases.

The compounds of the present invention may show good acid pump inhibitory activity, less toxicity, good absorption, good distribution, good solubility, less protein binding affinity other than acid

pump, less drug-drug interaction, and good metabolic stability.

Some stereoisomers of the present invention may show a better property of phototoxicity.

Detailed Description of the Invention

5 In the compounds of the present invention:

Where R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 and R^8 are the C_1 - C_6 alkyl group, this C_1 - C_6 alkyl group may be a straight or branched chain group having one to six carbon atoms, and examples include, but are not limited to, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl, pentyl, 1-ethylpropyl and hexyl. Of these, C_1 - C_4 alkyl is preferred; C_1 - C_2 alkyl is more preferred; methyl is preferred for R^1 , R^2 , R^3 , R^5 , R^6 , R^7 and R^8 ; methyl and ethyl are preferred for R^4 .

10 Where R^3 is the C_3 - C_7 cycloalkyl group, this represents cycloalkyl group having three to seven carbon atoms, and examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Of these, C_3 - C_5 cycloalkyl group is preferred; cyclopropyl is more preferred.

Where R^3 is the C_3 - C_7 cycloalkyl C_1 - C_6 alkyl group, this represents the said C_1 - C_6 alkyl group substituted with the said C_3 - C_7 cycloalkyl group, and examples include, but are not limited to, cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylbutyl, cyclopropylpentyl, cyclopropylhexyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl. Of these, C_3 - C_5 cycloalkyl C_1 - C_4 alkyl group is preferred; C_3 - C_5 cycloalkyl C_1 - C_2 alkyl group is preferred; cyclopropylmethyl is more preferred.

20 Where the substituents of R^1 and R^4 are the C_1 - C_6 alkoxy group, this represents the oxygen atom substituted with the said C_1 - C_6 alkyl group, and examples include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, *sec*-butoxy and *tert*-butoxy, pentyloxy and hexyloxy. Of these, a C_1 - C_4 alkoxy is preferred; a C_1 - C_2 alkoxy is preferred; methoxy is more preferred.

25 Where R^5 , R^6 , R^7 and R^8 are the halogen atom, they may be a fluorine, chlorine, bromine or iodine atom. Of these, a fluorine atom and a chlorine atom are preferred.

Where the "moiety convertible *in vivo* into a hydroxy group" means a moiety transformable *in vivo* by e.g. hydrolysis and/or by an enzyme, e.g. an esterase into a hydroxyl group. Examples of the moiety include, but are not limited to, ester and ether groups which may be hydrolyzed easily *in vivo*. Such moieties have known to those skilled in the art as 'pro-moieties' as described, for example, in "Design of Prodrugs" by H. Bundgaard (Elsevier, 1985). Preferred moieties convertible *in vivo* into a hydroxyl group are e.g. C_1 - C_6 alkyl carbonyl oxy group and C_1 - C_6 alkyl carbonyl oxy methyl oxy group.

Where -A-B- is -O-CH₂- or -S-CH₂-, -A- corresponds -O- or -S- and -B- corresponds -CH₂-.

Where -A-B- is -CH₂-O- or -CH₂-S-, -A- corresponds -CH₂- and -B- corresponds -O- or -S-.

35 The term "treating" and "treatment", as used herein, refers to curative, palliative and prophylactic treatment, including reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.

Preferred class of compounds of the present invention are those compounds of formula (I) or a pharmaceutically acceptable salt thereof, each as described herein, in which:

40 (a) -A-B- is -O-CH₂- or -CH₂-O-;

- (b) R¹ is a C₁-C₄ alkyl group;
- (c) R¹ is a C₁-C₂ alkyl group;
- (d) R¹ is a methyl group;
- (e) R² is a C₁-C₂ alkyl group;
- 5 (f) R² is a methyl group;
- (g) R³ is a C₁-C₄ alkyl group;
- (h) R³ is a C₁-C₂ alkyl group;
- (i) R³ is a methyl group;
- (j) R⁴ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 substituent selected from the group
- 10 consisting of a hydroxy group and a C₁-C₄ alkoxy group;
- (k) R⁴ is a C₁-C₂ alkyl group being unsubstituted or substituted with 1 substituent selected from the group consisting of a hydroxy group and a C₁-C₄ alkoxy group;
- (l) R⁴ is a C₁-C₂ alkyl group being unsubstituted or substituted with a hydroxy group;
- (m) R⁴ is a methyl group, an ethyl group or a 2-hydroxyethyl group;
- 15 (n) R⁵, R⁶, R⁷ and R⁸ are independently a hydrogen atom, a halogen atom or a C₁-C₂ alkyl group;
- (o) R⁵, R⁶, R⁷ and R⁸ are independently a hydrogen atom, a fluorine atom, a chlorine atom, or a methyl group;
- (p) R⁵, R⁶, R⁷ and R⁸ are independently a hydrogen atom or a methyl group
- (q) R⁵ is a hydrogen atom, a fluorine atom or a methyl group;
- 20 (r) R⁶ is a hydrogen atom;
- (s) R⁷ is a hydrogen atom or a fluorine atom; and
- (t) R⁸ is a hydrogen atom;

Of these classes of compounds, any combination among (a) to (t) is also preferred.

Preferred compounds of the present invention are those compounds of formula (I) or a

25 pharmaceutically acceptable salt thereof, each as described herein, in which:

- (A) -A-B- is -O-CH₂-, -S-CH₂-, -CH₂-O- or -CH₂-S-; R¹ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 to 2 substituents independently selected from the group consisting of a hydroxy group and a C₁-C₄ alkoxy group; R² is a C₁-C₄ alkyl group; R³ is a C₁-C₄ alkyl group, C₃-C₇ cycloalkyl group or C₃-C₇ cycloalkyl C₁-C₄ alkyl group; R⁴ is a C₁-C₄ alkyl group being unsubstituted or
- 30 substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom, a hydroxy group and a C₁-C₄ alkoxy group; and R⁵, R⁶, R⁷ and R⁸ are independently a hydrogen atom, a halogen atom or a C₁-C₆ alkyl group;
- (B) -A-B- is -O-CH₂-, or -CH₂-O-; R¹, R² and R³ are independently a C₁-C₄ alkyl group; R⁴ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 substituent selected from the group consisting of a
- 35 hydroxy group and a C₁-C₄ alkoxy group; R⁵ and R⁷ are independently a hydrogen atom, a halogen atom or a C₁-C₄ alkyl group; and R⁶ and R⁸ are each hydrogen atom;
- (C) -A-B- is -O-CH₂-, or -CH₂-O-; R¹, R² and R³ are independently a C₁-C₂ alkyl group; R⁴ is a C₁-C₂ alkyl group being unsubstituted or substituted with a hydroxy group; R⁵ and R⁷ are independently a hydrogen atom or a C₁-C₂ alkyl group; and R⁶ and R⁸ are each hydrogen atom;
- 40 (D) -A-B- is -O-CH₂-, or -CH₂-O-; R¹ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 to 2

substituents independently selected from the group consisting of a hydroxy group and a C₁-C₄ alkoxy group; R² is a C₁-C₄ alkyl group; R³ is a C₁-C₄ alkyl group, C₃-C₇ cycloalkyl group or C₃-C₇ cycloalkyl C₁-C₄ alkyl group; R⁴ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom, a hydroxy group and a C₁-C₄ alkoxy group; R⁵ and R⁷ are independently a hydrogen atom, a halogen atom or a C₁-C₄ alkyl group; and R⁶ and R⁸ are each hydrogen atom;

(E) -A-B- is -O-CH₂-, -S-CH₂-, -CH₂-O- or -CH₂-S-; R¹ and R² are independently a C₁-C₄ alkyl group; R³ is a C₁-C₄ alkyl group, C₃-C₇ cycloalkyl group or C₃-C₇ cycloalkyl C₁-C₄ alkyl group; R⁴ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom, a hydroxy group and a C₁-C₄ alkoxy group; R⁵ and R⁷ are independently a hydrogen atom, a halogen atom or a C₁-C₄ alkyl group; and R⁶ and R⁸ are each hydrogen atom;

(F) -A-B- is -O-CH₂-, -S-CH₂-, -CH₂-O- or -CH₂-S-; R¹ and R² are each methyl group; R³ is a C₁-C₄ alkyl group, C₃-C₇ cycloalkyl group or C₃-C₇ cycloalkyl C₁-C₄ alkyl group; R⁴ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom, a hydroxy group and a C₁-C₄ alkoxy group; R⁵ and R⁷ are independently a hydrogen atom, a halogen atom or a C₁-C₄ alkyl group; and R⁶ and R⁸ are each hydrogen atom;

(G) -A-B- is -O-CH₂-, -S-CH₂-, -CH₂-O- or -CH₂-S-; R¹ and R² are each methyl group; R³ is a C₁-C₄ alkyl group, C₃-C₇ cycloalkyl group or C₃-C₇ cycloalkyl C₁-C₄ alkyl group; R⁴ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of a halogen atom, a hydroxy group and a C₁-C₄ alkoxy group; R⁵ and R⁷ are independently a hydrogen atom, a halogen atom or a C₁-C₂ alkyl group; and R⁶ and R⁸ are each hydrogen atom;

(H) -A-B- is -O-CH₂-, -S-CH₂-, -CH₂-O- or -CH₂-S-; R¹ and R² are each methyl group; R³ is a C₁-C₄ alkyl group; R⁴ is a C₁-C₄ alkyl group being unsubstituted or substituted 1 substituent selected from the group consisting of a hydroxy group and a C₁-C₄ alkoxy group; R⁵ and R⁷ are independently a hydrogen atom, a halogen atom or a methyl group; and R⁶ and R⁸ are each hydrogen atom;

(I) -A-B- is -O-CH₂-, -S-CH₂-, -CH₂-O- or -CH₂-S-; R¹ and R² are each methyl group; R³ is a C₁-C₂ alkyl group; R⁴ is a C₁-C₂ alkyl group being unsubstituted or substituted with a hydroxy group; R⁵ and R⁷ are independently a hydrogen atom or a methyl group; and R⁶ and R⁸ are each hydrogen atom;

(J) -A-B- is -O-CH₂-, or -CH₂-O-; R¹, R² and R³ are independently a C₁-C₄ alkyl group; R⁴ is a C₁-C₄ alkyl group being unsubstituted or substituted with 1 substituent selected from the group consisting of a hydroxy group and a C₁-C₄ alkoxy group; and R⁵, R⁶, R⁷ and R⁸ are independently a hydrogen atom, a halogen atom or a C₁-C₄ alkyl group;

(K) -A-B- is -CH₂-O-; R¹, R² and R³ are independently a methyl group; R⁴ is a C₁-C₂ alkyl group being unsubstituted or substituted with a hydroxy group; R⁵ and R⁷ are independently a hydrogen atom or methyl group; and R⁶ and R⁸ are each hydrogen atom;

(L) -A-B- is -O-CH₂-, or -CH₂-O-; R¹, R² and R³ are independently a C₁-C₆ alkyl group; R⁴ is a C₁-C₆ alkyl group being unsubstituted or substituted with 1 substituent selected from the group consisting of a hydroxy group and a C₁-C₆ alkoxy group; R⁵ is a hydrogen atom, a fluorine atom or a C₁-C₆ alkyl group; R⁷ is a hydrogen atom, a halogen atom or a C₁-C₆ alkyl group; R⁶ and R⁸ are independently a

hydrogen atom, a halogen atom or a C₁-C₆ alkyl group;

(M) A-B- is -O-CH₂-, or -CH₂-O-; R¹, R² and R³ are independently a C₁-C₆ alkyl group; R⁴ is a C₁-C₆ alkyl group being unsubstituted or substituted with 1 substituent selected from the group consisting of a hydroxy group and a C₁-C₆ alkoxy group; R⁵ is a hydrogen atom, a fluorine atom or a C₁-C₆ alkyl group; R⁷ is a hydrogen atom or a halogen atom; and R⁶ and R⁸ are independently a hydrogen atom, a halogen atom or a C₁-C₆ alkyl group.

The compounds of formula (I) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers.

Included within the scope of the present invention are all stereoisomers and geometric isomers of the compounds of formula (I), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemate, DL-tartrate or DL-arginine.

One embodiment of the invention provides a compound selected from the group consisting of:

- (-)-8-(3,4-Dihydro-2H-chromen-4-ylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- (+)-8-(3,4-Dihydro-2H-chromen-4-ylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- (+)-8-(3,4-Dihydro-2H-chromen-4-ylamino)-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- (+)-N-(2-Hydroxyethyl)-N,2,3-trimethyl-8-[(5-methyl-3,4-dihydro-2H-chromen-4-yl)amino]imidazo[1,2-a]pyridine-6-carboxamide;
- (-)-8-[(7-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- (-)-8-[(7-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- (+)-8-[(7-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- (-)-8-[(5,7-Difluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- (+)-8-[(5,7-Difluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- (+)-8-[(5,7-Difluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- (-)-8-[(5-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- (+)-8-[(5-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide;
- (-)-8-[(5-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;
- (+)-8-[(5-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide;

(-)-8-[(6-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;

(+)-8-[(6-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide;

5 (-)-8-[(8-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;

(+)-8-[(8-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;

10 (-)-*N*-(2-Hydroxyethyl)-*N*,2,3-trimethyl-8-[(7-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide;

(+)-*N*-(2-Hydroxyethyl)-*N*,2,3-trimethyl-8-[(7-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide;

(-)-*N,N*,2,3-Tetramethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide; and

15 (+)-*N,N*,2,3-Tetramethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide;

or a pharmaceutically acceptable salt thereof.

Preferred stereoisomers of the compounds of formula (I) are R form with respect to a chiral center where the carbon atom on the chromane ring binds to the nitrogen atom.

20 Pharmaceutically acceptable salts of a compound of formula (I) include the acid addition salts (including disalts) thereof.

Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, 25 hexafluorophosphate, hibenzoate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate salts.

30 For a review on suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). A pharmaceutically acceptable salt of a compound of formula (I) may be readily prepared by mixing together solutions of the compound of formula (I) and the desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. The degree of 35 ionization in the salt may vary from completely ionized to almost non-ionized.

Pharmaceutically acceptable salts of the compounds of the invention include both unsolvated and solvated forms. The term "solvate" is used herein to describe a molecular complex comprising a compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.

40 Pharmaceutically acceptable solvates in accordance with the invention include hydrates and

solvates wherein the solvent of crystallization may be isotopically substituted, e.g. D₂O, d₆-acetone, d₆-DMSO.

Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblan (August 1975).

The compounds of formula (I) may exist in one or more crystalline forms. These polymorphs, including mixtures thereof are also included within the scope of the present invention.

The present invention includes all pharmaceutically acceptable isotopically-labeled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.

Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as ²H and ³H, carbon, such as ¹¹C, ¹³C and ¹⁴C, chlorine, such as ³⁶Cl, fluorine, such as ¹⁸F, iodine, such as ¹²³I and ¹²⁵I, nitrogen, such as ¹³N and ¹⁵N, oxygen, such as ¹⁵O, ¹⁷O and ¹⁸O, phosphorus, such as ³²P, and sulphur, such as ³⁵S.

Certain isotopically-labeled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, i.e. ³H, and carbon-14, i.e. ¹⁴C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.

Substitution with heavier isotopes such as deuterium, i.e. ²H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.

Substitution with positron emitting isotopes, such as ¹¹C, ¹⁸F, ¹⁵O and ¹³N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying examples and preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.

All of the compounds of the formula (I) can be prepared by the procedures described in the general methods presented below or by the specific methods described in the examples section and the preparations section, or by routine modifications thereof. The present invention also encompasses any one or more of these processes for preparing the compounds of formula (I), in addition to any novel intermediates used therein.

General Synthesis

The compounds of the present invention may be prepared by a variety of processes well known for the preparation of compounds of this type, for example as shown in the following Method A.


Unless otherwise indicated, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, A and B in the following methods are as

defined above. All starting materials in the following general syntheses may be commercially available or obtained by conventional methods known to those skilled in the art, such as WO99/55706 and WO 02/20523 and the disclosures of which are incorporated herein by references.

5 **Method A**

This illustrates the preparation of compounds of formula (I).

Reaction Scheme A



In Reaction Scheme A, R^a is a carboxy-protecting group; R^{1a} is R^1 as defined above or R^1 wherein hydroxy group is protected by a hydroxy-protecting group; and X is a leaving group.

10 The term "carboxy-protecting group", as used herein, signifies a protecting group capable of being cleaved by various means to yield a carboxy group, such as for example, a C_1 - C_6 alkyl group, halo C_1 - C_6 alkyl group or aryl C_1 - C_6 alkyl group. Of these, a C_1 - C_6 alkyl group and an aryl C_1 - C_6 alkyl group are preferred.

15 The term "hydroxy-protecting groups", as used herein, signifies a protecting group capable of being cleaved by various means to yield a hydroxy group, such as hydrogenolysis, hydrolysis, electrolysis or photolysis, and such hydroxy-protecting groups are described in Protective Groups in Organic Synthesis edited by T. W. Greene et al. (John Wiley & Sons, 1999). Such as for example, C_1 - C_4 alkoxycarbonyl, C_1 - C_4 alkylcarbonyl, tri- C_1 - C_4 alkylsilyl or tri- C_1 - C_4 alkylarylsilyl groups, and C_1 - C_4 alkoxy- C_1 - C_4 alkyl groups. Suitable hydroxy-protecting groups include acetyl and *tert*-butyldimethylsilyl.

20 The term "leaving group", as used herein, signifies a group capable of being substituted by nucleophilic groups, such as a hydroxy group, amines or carboanions and examples of such leaving groups include halogen atoms, a alkylsulfonyl group and a phenylsulfonyl group. Of these, a bromine, a chlorine atom, a methylsulfonyl group, a trifluoromethylsulfonyl group and a 4-methylphenylsulfonyl group are preferred.

25 **Step A1**

In this step, the compound of formula (IV) is prepared by nucleophilic substitution of the compound of formula (III), which is commercially available or may be prepared by the method as described

in WO00/078751, with the compound of formula (II), which is commercially available or may be prepared by the methods as described in WO99/55706 and WO02/020523.

The reaction is normally and preferably effected in the presence of solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve reagents, at least to some extent. Examples of suitable solvents include: ethers, such as tetrahydrofuran (THF), ethylene glycol dimethyl ether and dioxane; amides, such as *N,N*-dimethylformamide (DMF), *N,N*-dimethylacetamide (DMA) and *N*-methyl-2-pyrrolidinone (NMP); nitriles, such as acetonitrile; and ketones, such as acetone; alcohols, such as 2-methyl-2-propanol, 1-butanol, 1-propanol, 2-propanol, ethanol and methanol; and sulfoxide, such as dimethyl sulfoxide (DMSO). Of these solvents, amides, ketones and alcohols are preferred. Acetone is more preferred.

The reaction may be carried out with or without a base. There is likewise no particular restriction on the nature of the bases used, and any base commonly used in reactions of this type may equally be used here. Examples of such bases include: alkali metal alkoxides, such as sodium methoxide, sodium ethoxide and potassium *tert*-butoxide; alkali metal carbonates, such as lithium carbonate, sodium carbonate, cesium carbonate, and potassium carbonate; alkali metal hydrogencarbonates, such as sodium hydrogencarbonate and potassium hydrogencarbonate; and organic amines, such as triethylamine, tripropylamine, tributylamine, dicyclohexylamine, *N,N*-diisopropylethylamine, *N*-methylpiperidine, *N*-methylmorpholine, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 1,5-diazabicyclo[4.3.0]non-5-ene (DBN). Of these, potassium carbonate is preferred.

The reaction may be carried out with or without an iodide. Examples of such iodides include: sodium iodide, potassium iodide and cesium iodide. Of these, sodium iodide and potassium iodide are preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting materials. However, in general, it is convenient to carry out the reaction at a temperature of from about 0°C to about 250°C. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the starting materials and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from about 5 minutes to about 72 hours will usually suffice.

Step A2

In this step, the desired compound of formula (I) is prepared by (A2a1) hydrolysis of the compound of formula (IV) prepared as described in Step A1 followed by (A2a2) condensing reaction with the compound of formula (IV) or (A2b) substituting reaction of the compound of formula (IV) with the compound of formula (V).

(A2a1) hydrolysis

The reaction is normally and preferably effected in the presence of solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve reagents, at least to some extent. Examples of

suitable solvents include: ether, such as tetrahydrofuran and dioxane; amides, such as *N,N*-dimethylformamide; alcohols, such as ethanol and methanol; and water. Of these solvents, methanol, tetrahydrofuran and water are preferred.

The reaction is carried out in the presence of a base. There is likewise no particular restriction on the nature of the bases used, and any base commonly used in reactions of this type may equally be used here. Examples of such bases include: alkali metal hydroxides, such as lithium hydroxide, sodium hydroxide and potassium hydroxide. Of these, sodium hydroxide is preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting materials. However, in general, it is convenient to carry out the reaction at a temperature of from about 0°C to about 100°C. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the starting materials and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from about 5 minutes to about 12 hours will usually suffice.

(A2a2) condensing reaction

The reaction is normally and preferably effected in the presence of solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve reagents, at least to some extent. Examples of suitable solvents include: halogenated hydrocarbons, such as dichloromethane, chloroform, and 1,2-dichloroethane; ethers, such as tetrahydrofuran and dioxane; amides, such as *N,N*-dimethylformamide and *N,N*-dimethylacetamide; and nitriles, such as acetonitrile. Of these solvents, halogenated hydrocarbons and amides are preferred; dichloromethane and *N,N*-dimethylformamide are more preferred.

The reaction is carried out in the presence of a condensing agent. There is likewise no particular restriction on the nature of the condensing agents used, and any condensing agent commonly used in reactions of this type may equally be used here. Examples of such condensing agents include: azodicarboxylic acid di-lower alkyl ester-triphenylphosphines, such as diethyl azodicarboxylate-triphenylphosphine; 2-halo-1-lower alkyl pyridinium halides, such as 2-chloro-1-methylpyridinium iodide and 2-bromo-1-ethylpyridinium tetrafluoroborate (BEP); diarylphosphorylazides, such as diphenylphosphorylazide (DPPA); chloroformates, such as ethyl chloroformate and isobutyl chloroformate; phosphorocyanidates, such as diethyl phosphorocyanidate (DEPC); imidazole derivatives, such as *N,N'*-carbonyldiimidazole (CDI); carbodiimide derivatives, such as *N,N'*-dicyclohexylcarbodiimide (DCC) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI); iminium salts, such as 2-(1*H*-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and tetramethyl fluoroformamidinium hexafluoro phosphate (TFFH); and phosphonium salts, such as benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP) and bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBrop). Of these, EDCI is preferred.

Reagents, such as 4-(*N,N*-dimethylamino)pyridine (DMAP), and *N*-hydroxybenzotriazole (HOBt), may be employed for this step. Of these, HOBt is preferred.

The reaction may be carried out with or without a base. There is likewise no particular restriction on the nature of the bases used, and any base commonly used in reactions of this type may equally be used here. Examples of such bases include: amines, such as *N*-methylmorpholine, triethylamine, diisopropylethylamine, *N*-methylpiperidine and pyridine. Of these, triethylamine and *N*-methylmorpholine are preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting materials. However, in general, it is convenient to carry out the reaction at a temperature of from about 0°C to about 80°C. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the starting materials and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from about 5 minutes to about 24 hours will usually suffice.

(A2b) substituting reaction

The reaction can be carried out by heating the reactants in the neat amino compound or in an inert solvent under standard condition. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve reagents, at least to some extent. Examples of suitable solvents include: ethers, such as ethylene glycol dimethyl ether, tetrahydrofuran and dioxane; amides, such as *N,N*-dimethylformamide and *N,N*-dimethylacetamide; nitriles, such as acetonitrile; and alcohols such as 2-methyl-2-propanol, 1-butanol, 1-propanol, 2-propanol, ethanol and methanol. Of these solvents, ethers and alcohols are preferred. Tetrahydrofuran is more preferred.

The reaction may be carried out with or without a catalyst. There is likewise no particular restriction on the nature of the catalysts used, and any catalysts commonly used in reactions of this type may equally be used here. Examples of such catalysts include: sodium cyanide or potassium cyanide. Of these, sodium cyanide is preferred.

The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting materials. However, in general, it is convenient to carry out the reaction at a temperature of from about 40°C to about 200°C. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the starting materials and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from about 30 minutes to about 24 hours will usually suffice.

Introduction of the hydroxy-protecting group

In the case where R^1 has a hydroxy group, if necessary, the reaction may be accomplished after protecting the hydroxy group, before the reaction affected by the hydroxy group.

The introduction of the hydroxy-protecting group can be carried out at an appropriate step.

This reaction is described in detail by T. W. Greene et al., *Protective Groups in Organic Synthesis*, 369-453, (1999), the disclosures of which are incorporated herein by reference. The following exemplifies

a typical reaction involving the protecting group *tert*-butyldimethylsilyl.

For example, when the hydroxy-protecting group is a " *tert*-butyldimethylsilyl ", this step is conducted by reacting with a desired hydroxy- protecting group halide in an inert solvent in the presence of a base.

5 Examples of suitable solvents include: halogenated hydrocarbons, such as dichloromethane, chloroform, carbon tetrachloride and 1,2-dichloroethane; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; aromatic hydrocarbons, such as benzene, toluene and nitrobenzene; amides, such as formamide, *N,N*-dimethylformamide, *N,N*-dimethylacetamide and hexamethylphosphoric triamide; or mixed solvents thereof. Of these, tetrahydrofuran or *N,N*-dimethylformamide is preferred.

10 Examples of the hydroxy-protecting group halide usable in the above reaction include trimethylsilyl chloride, triethylsilyl chloride, *tert*-butyldimethylsilyl chloride, *tert*-butyldimethylsilyl bromide, acetyl chloride are preferred.

 Examples of the base include alkali metal hydroxides such as lithium hydroxide, sodium hydroxide and potassium hydroxide, alkali metal carbonates such as lithium carbonate, sodium carbonate
15 and potassium carbonate, and organic amines such as triethylamine, tributylamine, *N*- methylmorpholine, pyridine, imidazole, 4-dimethylaminopyridine, picoline, lutidine, collidine, DBN and DBU. Out of these, triethylamine, imidazole, or pyridine is preferred. Upon use of an organic amine in the liquid form, it also serves as a solvent when used in large excess.

 Although the reaction temperature differs with the nature of the starting compound, the halide
20 and the solvent, it usually ranges from 0°C to 80°C (preferably 0 to 30°C). Although the reaction time differs with the reaction temperature or the like, it ranges from 10 minutes to 2 days (preferably 30 minutes to 1 day).

Deprotecting step

25 In the case where R^{1a} has a protected hydroxy group, the deprotection reaction will follow to yield a hydroxy group. This reaction is described in detail by T. W. Greene et al., *Protective Groups in Organic Synthesis*, 369-453, (1999), the disclosures of which are incorporated herein by reference. The following exemplifies a typical reaction involving the protecting group *tert*-butyldimethylsilyl.

 The deprotection of the hydroxyl groups is carried out with an acid, such as acetic acid, hydrogen
30 fluoride, hydrogen fluoride-pyridine complex, or fluoride ion, such as tetrabutylammonium fluoride (TBAF).

 The deprotection reaction is normally and preferably effected in the presence of solvent. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve reagents, at least to some extent. Examples of suitable solvents include, but are not limited to: alcohol, such as methanol, ethanol or mixed
35 solvents thereof.

 The deprotection reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. The preferred reaction temperature will depend upon such factors as the nature of the solvent, and the starting materials. However, in general, it is convenient to carry out the reaction at a temperature of from about 0°C to about 100°C. The time required for the
40 reaction may also vary widely, depending on many factors, notably the reaction temperature and the

nature of the starting materials and solvent employed. However, provided that the reaction is effected under the preferred conditions outlined above, a period of from about 10 minutes to about 24 hours, will usually suffice.

5 The compounds of formula (I), and the intermediates in the above-mentioned preparation methods can be isolated and purified by conventional procedures, such as distillation, recrystallization or chromatographic purification.

 Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods
10 such as precipitation, crystallization, freeze-drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.

 Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC).

15 Alternatively, a method of optical resolution of a racemate (or a racemic precursor) can be appropriately selected from conventional procedures, for example, preferential crystallization, or resolution of diastereomeric salts between a basic moiety of the compound of formula (I) and a suitable optically active acid such as tartaric acid.

20 Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze-drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.

 They may be administered alone or in combination with one or more other compounds of the
25 invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a pharmaceutical composition or formulation in association with one or more pharmaceutically acceptable carriers or excipients. The term "carrier" or "excipient" is used herein to describe any ingredient other than the compound(s) of the invention. The choice of carrier or excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient
30 on solubility and stability, and the nature of the dosage form.

 Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995).

35

ORAL ADMINISTRATION

 The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.

40 Formulations suitable for oral administration include solid formulations such as, for example, tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews,

multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.

Liquid formulations include, for example, suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.

The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001).

For tablet dosage forms, depending on dose, the drug may make up from about 1 wt% to about 80 wt% of the dosage form, more typically from about 5 wt% to about 60 wt% of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from about 1 wt% to about 25 wt%, preferably from about 5 wt% to about 20 wt% of the dosage form.

Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.

Tablets may also optionally comprise surface-active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from about 0.2 wt% to about 5 wt% of the tablet, and glidants may comprise from about 0.2 wt% to about 1 wt% of the tablet.

Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from about 0.25 wt% to about 10 wt%, preferably from about 0.5 wt% to about 3 wt% of the tablet.

Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.

Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.

Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tableting.

The final formulation may comprise one or more layers and may be coated or uncoated; it may even be

encapsulated.

The formulation of tablets is discussed in "*Pharmaceutical Dosage Forms: Tablets, Vol. 1*", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247-6918-X).

Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma *et al*, Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in WO00/35298.

PARENTERAL ADMINISTRATION

The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.

Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from about 3 to about 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.

The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.

The solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.

Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres.

TOPICAL ADMINISTRATION

The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated - see, for example, *J Pharm Sci*, **88** (10), 955-958 by Finnin

and Morgan (October 1999).

Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. Powderject™, Bioject™, etc.) injection.

Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

INHALED/INTRANASAL ADMINISTRATION

The compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.

The pressurized container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.

Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as *L*-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.

A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from about 1µg to about 20mg of the compound of the invention per actuation and the actuation volume may vary from about 1µl to about 100µl. A typical formulation may comprise a compound of formula (I), propylene glycol, sterile water, ethanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.

Suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration. Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, poly(DL-lactic-co-glycolic acid (PGLA). Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a

valve which delivers a metered amount. Units in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from about 1 to about 100 μg of the compound of formula (I). The overall daily dose will typically be in the range about 50 μg to about 20 mg which may be administered in a single dose or, more usually, as divided doses throughout the day.

5

RECTAL/INTRA-VAGINAL ADMINISTRATION

The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.

10

Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

15 OCULAR/AURAL ADMINISTRATION

The compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g. absorbable gel sponges, collagen) and non-biodegradable (e.g. silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelatin gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.

20

Formulations for ocular/aural administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release.

25 OTHER TECHNOLOGIES

The compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.

30

Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in WO91/11172, WO94/02518 and WO98/55148.

40 KIT-OF-PARTS

Inasmuch as it may be desirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for coadministration of the compositions.

Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I) in accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.

The kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.

DOSAGE

For administration to human patients, the total daily dose of the compounds of the invention is typically in the range of about 0.05 mg to about 500 mg depending, of course, on the mode of administration, preferred in the range of about 0.1 mg to about 400 mg and more preferred in the range of about 0.5 mg to about 300 mg. For example, oral administration may require a total daily dose of from about 1 mg to about 300 mg, while an intravenous dose may only require from about 0.5 mg to about 100 mg. The total daily dose may be administered in single or divided doses.

These dosages are based on an average human subject having a weight of about 65 kg to about 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.

COMBINATIONS

As discussed above, a compound of the invention exhibits acid pump inhibitory activity. An acid pump antagonist of the present invention may be usefully combined with another pharmacologically active compound, or with two or more other pharmacologically active compounds, particularly in the treatment of gastroesophageal reflux disease. For example, an acid pump antagonist, particularly a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined above, may be administered simultaneously, sequentially or separately in combination with one or more agents selected from:

- (i) histamine H₂ receptor antagonists, e.g. ranitidine, famotidine, nizatidine, cimetidine, roxatidine and rabeprazole;
- (ii) proton pump inhibitors, e.g. omeprazole, esomeprazole, pantoprazole, rabeprazole, tenatoprazole, ilaprazole and lansoprazole;
- (iii) oral antacid mixtures, e.g. Maalox[®], Aludrox[®] and Gaviscon[®];
- (iv) mucosal protective agents, e.g. polaprezinc, ecabet sodium, rebamipide, teprenone, cetraxate, sucralfate, chloropylline-copper and plaunotol;
- (v) anti-gastric agents, e.g. Anti-gastrin vaccine, itriglumide and Z-360;

- (vi) 5-HT₃ antagonists, e.g. dolasetron, palonosetron, alosetron, azasetron, ramosetron, mitrazapine, granisetron, tropisetron, E-3620, ondansetron and indisetron;
- (vii) 5-HT₄ agonists, e.g. tegaserod, mosapride, cinitapride and oxtripane;
- (viii) laxatives, e.g. Trifyba[®], Fybogel[®], Konsyl[®], Isogel[®], Regular[®], Celevac[®] and Normacol[®];
- 5 (ix) GABA_B agonists, e.g. baclofen and AZD-3355;
- (x) GABA_B antagonists, e.g. GAS-360 and SGS-742;
- (xi) calcium channel blockers, e.g. aranidipine, lacidipine, falodipine, azelnidipine, clinidipine, lomerizine, diltiazem, gallopamil, efonidipine, nisoldipine, amlodipine, lercanidipine, bevantolol, nicardipine, isradipine, benidipine, verapamil, nitrendipine, barnidipine, propafenone, manidipine, 10 bepridil, nifedipine, nilvadipine, nimodipine and fasudil;
- (xii) dopamine antagonists, e.g. metoclopramide, domperidone and levosulpiride;
- (xiii) Tachykinin (NK) antagonists, particularly NK-3, NK-2 and NK-1 antagonists, e.g. nepadutant, saredutant, talnetant, (αR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthridine-6-13-dione (TAK-637), 5-[[[(2R,3S)-2-15 [[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3-H-1,2,4-triazol-3-one (MK-869), lanepitant, dapitant and 3-[[[2-methoxy-5-(trifluoromethoxy)phenyl] methylamino]-2-phenyl-piperidine (2S,3S);
- (xiv) Helicobacter pylori infection agents, e.g. clarithromycin, roxithromycin, rokitamycin, flurithromycin, telithromycin, amoxicillin, ampicillin, temocillin, bacampicillin, aspoxicillin, sultamicillin, piperacillin, 20 lenampicillin, tetracycline, metronidazole, bithmuth citrate and bithmuth subsalicylate;
- (xv) nitric oxide synthase inhibitors, e.g. GW-274150, tilarginine, P54, guanidioethyldisulfide and nitroflurbiprofen;
- (xvi) vanilloid receptor 1 antagonists, e.g. AMG-517 and GW-705498;
- (xvii) muscarinic receptor antagonists, e.g. trospium, solifenacin, tolterodine, tiotropium, cimetroplum, 25 oxitropium, ipratropium, tiquizium, dalifenacin and imidafenacin;
- (xviii) calmodulin antagonists, e.g. squalamine and DY-9760;
- (xix) potassium channel agonists, e.g. pinacidil, tilisolol, nicorandil, NS-8 and retigabine;
- (xx) beta-1 agonists, e.g. dobutamine, denopamine, xamoterol, denopamine, docarpamine and xamoterol;
- 30 (xxi) beta-2 agonists, e.g. salbutamol; terbutaline, arformoterol, meluadrine, mabuterol, ritodrine, fenoterol, clenbuterol, formoterol, procaterol, tulobuterol, pirbuterol, bambuterol, tulobuterol, dopexamine and levosalbutamol;
- (xxii) beta agonists, e.g. isoproterenol and terbutaline;
- (xxiii) alpha 2 agonists, e.g. clonidine, medetomidine, lofexidine, moxonidine, tizanidine, guanfacine, 35 guanabenz, talipexole and dexmedetomidine;
- (xxiv) endthelin A antagonists, e.g. bonsetan, atrasentan, ambrisentan, clazosentan, sitaxsentan, fandosentan and darusentan;
- (xxv) opioid μ agonists, e.g. morphine, fentanyl and loperamide;
- (xxvi) opioid μ antagonists, e.g. naloxone, buprenorphine and alvimopan;
- 40 (xxvii) motilin agonists, e.g. erythromycin, mitemcinal, SLV-305 and atilomotin;

- (xxviii) ghrelin agonists, e.g. capromorelin and TZP-101;
- (xxix) AchE release stimulants, e.g. Z-338 and KW-5092;
- (xxx) CCK-B antagonists, e.g. itriglumide, YF-476 and S-0509;
- (xxxi) glucagon antagonists, e.g. NN-2501 and A-770077;
- 5 (xxxii) piperacillin, lenampicillin, tetracycline, metronidazole, bithmuth citrate and bithmuth subsalicylate;
- (xxxiii) Glucagon-like peptide-1 (GLP-1) antagonists, e.g. PNU-126814;
- (xxxiv) small conductance calcium-activated potassium channel 3 (SK-3) antagonists, e.g. apamin, dequalinium, atracurium, pancuronium and tubocurarine.

10 **Method for assessing biological activities:**

The acid pump inhibitory activity and other biological activities of the compounds of this invention were determined by the following procedures. Symbols have their usual meanings: mL (milliliter(s)), μ L (microlitter(s)), Kg (kirogram(s)), g (gram(s)), mg (milligram(s)), μ g (microgram(s)), pmol (pico molar(s)), mmol (milli molar(s)), M (molar mass (m^3/mol)), mM (milli molar mass), μ M (micro molar mass), quant. (quantitative yield), nm (nanometer(s)), min (minute(s)) Cat# (catalog number).

Preparation of gastric vesicles from fresh porcine stomachs

The porcine gastric vesicles for Porcine gastric H^+/K^+ -ATPase inhibition assays were prepared from mucous membrane in fresh porcine stomachs by homogenization with a tight-fitted polytetrafluoroethylene (Teflon®) homogenizer in 0.25 M sucrose at 4 °C. The crude pellet was removed with centrifugation at 20,000 g for 30 min. Then supernatant was centrifuged at 100,000 g for 30 min. The resulting pellet was re-suspended in 0.25 M sucrose, and then subjected to density gradient centrifugation at 132,000 g for 90 min. The gastric vesicles were collected from interface on 0.25 M sucrose layer containing 7% Ficoll™ PM400(Amersham Biosciences). This procedure was performed in a cold room.

Ion-leaky Porcine gastric H^+/K^+ -ATPase inhibition

Ion-leaky porcine gastric H^+/K^+ -ATPase_inhibition was measured according to the modified method described in *Biochemical Pharmacology*, 1988, 37, 2231-2236.

The isolated vesicles were lyophilized, and then kept in deep-freezer until use. For enzyme assay, lyophilized vesicles were reconstituted with 3 mM MgSO_4 containing 40 mM Bis-tris (pH 6.4 at 37°C).

Enzyme reaction was performed incubating 5 mM KCl, 3 mM Na_2ATP , 3 mM MgSO_4 and 1.0 μ g of reconstituted vesicles for 30 minutes at 37°C in a final 60 μ L of reaction mixture (40 mM Bis-tris, pH 6.4) with or without the test compound. Enzyme reaction was stopped by adding 10% sodium dodecyl sulphate (SDS). Released inorganic phosphate from ATP was detected by incubation with mixture of 1 part of 35 mM ammonium molybdate tetrahydrate in 15 mM Zinc acetate hydrate and 4 parts of 10% ascorbic acid (pH 5.0), resulting in phosphomolybdate, which has optical density at 750 nm. All example compounds showed potent inhibitory activity.

The results of IC_{50} values of the inhibitory activity for the compounds of following examples are shown in Table 1.

Table 1.

Example No.	IC ₅₀ (μM)
1-1	0.085
1-2	0.0619
1-3	0.0278
2-1	0.0497
2-2	0.0811
2-3	0.064
3-1	0.103
3-2	0.125
3-3	0.0676
4-1	0.0871
4-2	0.273
4-3	0.112
5-1	0.0947
5-2	0.0862
5-3	0.093
6-1	0.0139
6-2	0.0409
6-3	0.0157
7-1	0.0266
7-2	0.0205
7-3	0.0559
8-1	0.02
8-2	0.023
8-3	0.049
9-1	0.05
9-2	0.0159
9-3	0.0532
10-1	0.0751
10-2	0.0511
10-3	0.091
11-1	0.0486
11-2	0.0538
11-3	0.101
12-1	0.0208
12-2	0.197
12-3	0.0811
13-1	0.25
13-2	1.1
13-3	0.17
14-1	0.294
14-2	0.12
14-3	0.17
15-1	0.0409
15-2	0.23
15-3	0.37
16-1	0.331
16-2	0.1
16-3	0.18
17-1	0.064
17-2	0.043
17-3	0.091
18-1	0.35
18-2	0.3
18-3	0.24
19-1	0.39
19-2	0.6
19-3	0.5

Ion-tight porcine gastric H⁺/K⁺-ATPase inhibition

Ion-tight porcine gastric H⁺/K⁺-ATPase inhibition was measured according to the modified method described in *Biochemical Pharmacology*, 1988, 37, 2231-2236.

5 The isolated vesicles were kept in deep-freezer until use. For enzyme assay, vesicles were diluted with 3 mM MgSO₄ containing 5 mM Tris (pH 7.4 at 37°C).

Enzyme reaction was performed incubating 150 mM KCl, 3 mM Na₂ATP, 3 mM MgSO₄, 15 μM valinomycin and 3.0 μg of vesicles for 30 minutes at 37°C in a final 60 μl of reaction mixture (5mM Tris, pH 7.4) with or without the test compound. Enzyme reaction was stopped by adding 10% SDS. Released
10 inorganic phosphate from ATP was detected by incubating with mixture of 1 part of 35 mM ammonium molybdate tetrahydrate in 15 mM Zinc acetate hydrate and 4 parts of 10% ascorbic acid (pH 5.0), resulting in phosphomolybdate, which has optical density at 750 nm.

Canine kidney Na⁺/K⁺-ATPase inhibition

15 The powdered canine kidney Na⁺/K⁺-ATPase (Sigma) was reconstituted with 3 mM MgSO₄ containing 40 mM Tris (pH 7.4 at 37°C). Enzyme reaction was performed incubating 100 mM NaCl, 2 mM KCl, 3 mM Na₂ATP, 3 mM MgSO₄ and 12 μg of enzyme for 30 minutes at 37°C in a final 60 μl of reaction mixture (40 mM Tris, pH 7.4) with or without the test compound. Enzyme reaction was stopped by adding 10% SDS. Released inorganic phosphate from ATP was detected by incubating with mixture of 1 part of 35
20 mM ammonium molybdate tetrahydrate in 15 mM Zinc acetate hydrate and 4 parts of 10% ascorbic acid (pH 5.0), resulting in phosphomolybdate, which has optical density at 750 nm.

Inhibition of acid secretion in the gastric lumen-perfused rat

Acid secretion in the gastric lumen-perfused rat was measured according to Watanabe et al.
25 [Watanabe K et al., *J. Physiol. (Paris)* 2000; 94: 111-116].

Male Sprague-Dawley rats, 8 weeks old, deprived of food for 18 hours before the experiment with free access to water, were anesthetized with urethane (1.4 g/kg, i.p.) and tracheotomized. After a middle abdominal incision, a dual polyethylene cannula was inserted into the forestomach and the stomach was perfused with saline (37 °C, pH 5.0) at a rate of 1 ml/min. The acid output in the perfusate was determined
30 at 5 minutes interval by titration with 0.02 M NaOH to pH 5.0. After the determination of basal acid secretion for 30 min, the acid secretion was stimulated by a continuous intravenous infusion of pentagastrin (16 μg/kg/h). The test compounds were administered by an intravenous bolus injection or intraduodenal administration after the stimulated acid secretion reached a plateau phase. The acid secretion was monitored after the administration.

35 The activity was evaluated either inhibition of total acid secretion from 0 hours to 1.5 or 3.5 hours after administration or the maximum inhibition after administration.

The compound of Example 5-3 showed a good inhibitory activity.

Inhibition of gastric acid secretion in the Heidenhain pouch dog

40 Male Beagle dogs weighing 7 - 15 kg with Heidenhain pouch [Heidenhain R: *Arch Ges Physiol*.

1879; 19: 148-167] were used. The animals were allowed to recover from surgery for at least three weeks before the experiments. The animals were kept at a 12 hour light-dark rhythm, housed singly. They received standard food once daily at 11:00 a.m. and tap water ad libitum, and were fasted overnight prior to the experiment, with free access to water. Gastric juice samples were collected throughout the experiment by gravity drainage every 15 min. Acidity in the gastric juice was measured by titration to the end point of pH 7.0. Acid secretion was stimulated by a continuous intravenous infusion of histamine (80 $\mu\text{g/kg/h}$). Oral or intravenous bolus administration of the test compounds was done 90 minutes after commencement of the histamine infusion. The acid secretion was monitored after the administration. The activity was evaluated by the maximum inhibition relative to the corresponding control value.

Human dofetilide binding

Human ether a-go-go related gene (HERG) transfected HEK293S cells were prepared and grown in-house. Cell paste of HEK-293 cells expressing the HERG product can be suspended in 10-fold volume of 50 mM Tris buffer adjusted at pH 7.5 at 25 °C with 2 M HCl containing 1 mM MgCl_2 , 10 mM KCl. The cells were homogenized using a Polytron homogenizer (at the maximum power for 20 seconds) and centrifuged at 48,000 g for 20 minutes at 4°C. The pellet was resuspended, homogenized and centrifuged once more in the same manner. The resultant supernatant was discarded and the final pellet was resuspended (10-fold volume of 50 mM Tris buffer) and homogenized at the maximum power for 20 seconds. The membrane homogenate was aliquoted and stored at -80°C until use. An aliquot was used for protein concentration determination using a Protein Assay Rapid Kit (wako) and Spectra max plate reader (Wallac). All the manipulation, stock solution and equipment were kept on ice at all times. For saturation assays, experiments were conducted in a total volume of 200 μl . Saturation was determined by incubating 36 μl of [^3H]-dofetilide, and 160 μl of membrane homogenates (20-30 μg protein per well) for 60 minutes at room temperature in the absence or presence of 10 μM dofetilide at final concentrations (4 μl) for total or nonspecific binding, respectively. All incubations were terminated by rapid vacuum filtration over PEI soaked glass fiber filter papers using Skatron cell harvester followed by two washes with 50 mM Tris buffer (pH 7.4 at 25 °C). Receptor-bound radioactivity was quantified by liquid scintillation counting using Packard LS counter.

For the competition assay, compounds were diluted in 96 well polypropylene plates as 4-point dilutions in semi-log format. All dilutions were performed in DMSO first and then transferred into 50 mM Tris buffer (pH 7.4 at 25 °C) containing 1 mM MgCl_2 , 10 mM KCl so that the final DMSO concentration became equal to 1%. Compounds were dispensed in triplicate in assay plates (4 μl). Total binding and nonspecific binding wells were set up in 6 wells as vehicle and 10 μM dofetilide at final concentration, respectively. The radioligand was prepared at 5.6x final concentration and this solution was added to each well (36 μl). The assay was initiated by addition of YSi poly-L-lysine SPA beads (50 μl , 1 mg/well) and membranes (110 μl , 20 μg /well). Incubation was continued for 60 minutes at room temperature. Plates were incubated for a further 3 hours at room temperature for beads to settle. Receptor-bound radioactivity was quantified by counting Wallac MicroBeta plate counter.

Caco-2 permeability

Caco-2 permeability was measured according to the method described in Shiyin Yee,

Pharmaceutical Research, 763 (1997).

Caco-2 cells were grown on filter supports (Falcon HTS multiwell insert system) for 14 days. Culture medium was removed from both the apical and basolateral compartments and the monolayers were preincubated with pre-warmed 0.3 ml apical buffer and 1.0 ml basolateral buffer for 0.5 hour at 37°C in a shaker water bath at 50 cycles/min. The apical buffer consisted of Hanks Balanced Salt Solution, 25 mM D-glucose monohydrate, 20 mM 2-morpholinoethanesulphonic acid (MES) Biological Buffer, 1.25 mM CaCl₂ and 0.5 mM MgCl₂ (pH 6.5). The basolateral buffer consisted of Hanks Balanced Salt Solution, 25 mM D-glucose monohydrate, 20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES) Biological Buffer, 1.25 mM CaCl₂ and 0.5 mM MgCl₂ (pH 7.4). At the end of the preincubation, the media was removed and test compound solution (10 µM) in buffer was added to the apical compartment. The inserts were moved to wells containing fresh basolateral buffer at 1 hour. Drug concentration in the buffer was measured by LC/MS analysis.

Flux rate (F, mass/time) was calculated from the slope of cumulative appearance of substrate on the receiver side and apparent permeability coefficient (P_{app}) was calculated from the following equation.

$$P_{app} \text{ (cm/sec)} = (F * VD) / (SA * MD)$$

where SA is surface area for transport (0.3 cm²), VD is the donor volume (0.3 ml), MD is the total amount of drug on the donor side at t = 0. All data represent the mean of 2 inserts. Monolayer integrity was determined by Lucifer Yellow transport.

Half-life in human liver microsomes (HLM)

Test compounds (1 µM) were incubated with 3.3 mM MgCl₂ and 0.78 mg/mL HLM (HL101) in 100 mM potassium phosphate buffer (pH 7.4) at 37°C on the 96-deep well plate. The reaction mixture was split into two groups, a non-P450 and a P450 group. NADPH was only added to the reaction mixture of the P450 group. An aliquot of samples of P450 group was collected at 0, 10, 30, and 60 minutes time point, where 0 minutes time point indicated the time when NADPH was added into the reaction mixture of P450 group. An aliquot of samples of non-P450 group was collected at -10 and 65 minutes time point. Collected aliquots were extracted with acetonitrile solution containing an internal standard. The precipitated protein was spun down in centrifuge (2000 rpm, 15 min). The compound concentration in supernatant was measured by LC/MS/MS system.

The half-life value was obtained by plotting the natural logarithm of the peak area ratio of compounds/ internal standard versus time. The slope of the line of best fit through the points yields the rate of metabolism (k). This was converted to a half-life value using following equations:

$$\text{Half-life} = \ln 2 / k$$

In vitro drug-drug interaction studies for five major CYPs (fDDI)

CYP1A2 Test compounds (3 µM) were pre-incubated with recombinant CYP1A2 (Baculosome lot#21198 Invitrogen, 50 pmol P450/ml) in 100 mM K⁺Phosphate Buffer (pH 7.4) and 10 µM Vivid blue 1A2 probe (Invitrogen) as a substrate for 5 minutes at 30 °C. Reaction was initiated by adding a solution of a warmed NADPH-regenerating system A, which consists of 0.50 mM NADP and 10 mM MgCl₂, 6.2 mM DL-Isocitric acid and 0.5U/ml Isocitric Dehydrogenase (ICD). Plates were placed in the plate reader at 30 °C and were taken readings every 1.5 minutes, with a 10 second shake in between each reading for 15

cycles. Wavelengths of excitation/emission were 408/465 nm, respectively.

CYP2C9 Test compounds (3 μ M) were pre-incubated with recombinant CYP2C9 (Baculosome lot#20967 Invitrogen, 50 pmol P450/ml) in 100 mM K⁺Phosphate Buffer (pH 7.4) and 30 μ M MFC probe (Gentest) as a substrate for 5 minutes at 37 °C. Reaction was initiated by adding a solution of the warmed NADPH-regenerating system A. Plates were placed in the plate reader at 37 °C and were taken readings every 2.0 minutes, with a 10 second shake in between each reading for 15 cycles. Wavelengths of excitation /emission were 408 /535 nm, respectively.

CYP2C19 Test compounds (3 μ M) were pre-incubated with recombinant CYP2C19 (Baculosome lot#20795 Invitrogen, 5 pmol P450/ml) in 100 mM K⁺Phosphate Buffer (pH 7.4) and 10 μ M Vivid blue 2C19 probe (Invitrogen) as a substrate for 5 minutes at 37 °C. Reaction was initiated by adding a solution of the warmed NADPH-regenerating system A. Plates were placed in the plate reader at 37 °C and were taken readings every 1.5 minutes with a 10 second shake in between each reading for 15 cycles. Wavelengths of excitation /emission were 408 /465 nm, respectively.

CYP2D6 Test compounds (3 μ M) were pre-incubated with recombinant CYP2D6 (Baculosome lot#21248 Invitrogen, 20 pmol P450/ml) in 100 mM K⁺Phosphate Buffer (pH 7.4) and 1 μ M 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) probe (Gentest) as a substrate for 5 minutes at 37 °C. Reaction was initiated by adding a solution of a warmed NADPH-regenerating system B, which consists of 0.03 mM NADP and 10 mM MgCl₂, 6.2 mM DL-Isocitric acid and 0.5 U/ml ICD. Plates were placed in the plate reader at 37 °C and were taken readings every 2.0 minutes with a 10 second shake in between each reading for 15 cycles. Wavelengths of excitation /emission were 400 /465 nm, respectively.

CYP3A4 Test compounds (3 μ M) were pre-incubated with recombinant CYP3A4 (Baculosome lot#20814 Invitrogen, 5 pmol P450/ml) in 100 mM K⁺Phosphate Buffer (pH 7.4) and 2 μ M Vivid Red probe (Invitrogen) as a substrate for 5 minutes at 30 °C. Reaction was initiated by adding a solution of the warmed NADPH-regenerating system A. Plates were placed in the plate reader at 30 °C and were taken readings minimum intervals with a 10 second shake in between each reading for 15 cycles. Wavelengths of excitation /emission were 530 /595 nm, respectively.

Drug-drug interaction was evaluated by the rate of metabolite formation calculated with a slope (Time vs. Fluorescence units) in the linear region or the percentage of inhibition by test compounds calculated by the following equation.

Inhibition % = $\{(v_o - v_i)/v_o\} \times 100$, wherein v_o is a rate of control reaction (no test compounds) and v_i is a rate of reaction in the presence of test compound.

HERG assay

Human ether a-go-go related gene (HERG) transfected HEK293 cells are prepared and cultured in-house. The methodology for stable transfection of this channel in HEK cells can be found elsewhere (Z.Zhou et al., 1998, *Biophysical journal*, 74, 230-241). On the day of experimentation, the cells are harvested from culture flasks and stored as cell suspension in a standard external solution (see below of its composition). in the room atmosphere of 23 °C. Cells are studied between 0.5-5 hours after harvest.

HERG currents are studied using a standard patch clamp technique of the whole-cell mode.

During the experiment, the cells are superfused with a standard external solution of the following composition; (mM) NaCl, 130; KCl, 4; CaCl₂, 2; MgCl₂, 1; Glucose, 10; HEPES, 5; pH 7.4 with NaOH. Whole-cell recordings is made using a patch clamp amplifier and patch pipettes which have a resistance of 1-3MΩ when filled with the standard internal solution of the following composition; (mM); KCl, 130; MgATP, 5; MgCl₂, 1; HEPES, 10; EGTA 5, pH 7.2 with KOH. Only those cells with access resistances below 10 MΩ and seal resistances over 1GΩ are accepted for further experimentation. Series resistance compensation is applied up to a maximum of 80% without any leak subtraction. Following the achievement of whole cell configuration and sufficient time for cell dialysis with pipette solution (>5 min), the membrane is depolarized from a holding potential of - 80 mV to + 30mV for 1000 ms followed by a descending voltage ramp (rate 0.5 mV msec⁻¹) back to the holding potential. This depolarization and ramp is applied to the cells continuously every 4 seconds (0.25 Hz). The amplitude of the peak current elicited around -40 mV during the ramp is measured. Once stable evoked current responses of minimal changes in the amplitude are obtained in the external solution, the test compound is applied for 10-20 minutes with multiple dosing in a single cell. The cells are also exposed to high dose of dofetilide (5 μM), a specific IKr blocker, to evaluate the insensitive endogenous current.

All experiments are performed at 23±1 °C. Evoked membrane currents are recorded online on a computer, filtered at 500-1000 Hz (Bessel -3dB) and sampled at 1-2 KHz. Osmolarity and pH change induced by the test compound in external solution will be examined at the highest concentration.

The arithmetic mean of these ten values of peak current is calculated under control conditions and in the presence of drug. Percent decrease of I_N in each experiment is obtained by the normalized current value using the following formula: $I_N = (I_C - I_D) / (I_C - I_{dof}) \times 100$, where I_C is the mean current value under control conditions, I_D is the mean current value in the presence of test compound and I_{dof} is the mean current value in dofetilide application. Separate experiments are performed and pooled data of arithmetic mean from each experiment is defined as the result of the study.

Bioavailability in rat

Adult rats of the Sprague-Dawley strain were used. One to two days prior to the experiments all rats were prepared by cannulation of the right jugular vein under anesthesia. The cannula was exteriorized at the nape of the neck. Blood samples (0.2-0.3 mL) were drawn from the jugular vein at intervals up to 24 hours after intravenous or oral administrations of the test compound. The samples were frozen until analysis. Bioavailability was assessed by calculating the quotient between the area under plasma concentration curve (AUC) following oral administration or intravenous administration.

Bioavailability in dog

Adult Beagle dogs were used. Blood samples (0.2-0.5 mL) were drawn from the cephalic vein at intervals up to 24 hours after intravenous or oral administrations of the test compound. The samples were frozen until analysis. Bioavailability was assessed by calculating the quotient between the area under plasma concentration curve (AUC) following oral administration or intravenous administration.

Plasma protein binding

Plasma protein binding of the test compound (1 μ M) was measured by the method of equilibrium dialysis using 96-well plate type equipment. Spectra-Por®, regenerated cellulose membranes (molecular weight cut-off 12,000-14,000, 22 mm x 120 mm) were soaked for over night in distilled water, then for 20 minutes in 30% ethanol, and finally for 15 minutes in dialysis buffer (Dulbecco's phosphate buffered saline, pH7.4). Frozen plasma of human, Sprague-Dawley rats, and Beagle dogs were used. The dialysis equipment was assembled and added 150 μ L of compound-fortified plasma to one side of each well and 150 μ L of dialysis buffer to the other side of each well. After 4 hours incubation at 37 °C for 150 r.p.m, aliquots of plasma and buffer were sampled. The compound in plasma and buffer were extracted with 300 μ L of acetonitrile containing internal standard compounds for analysis. The concentration of the compound was determined with LC/MS/MS analysis.

The fraction of the compound unbound was calculated by the following equation:

$$f_u = 1 - \{ ([\text{plasma}]_{\text{eq}} - [\text{buffer}]_{\text{eq}}) / ([\text{plasma}]_{\text{eq}}) \}$$

wherein $[\text{plasma}]_{\text{eq}}$ and $[\text{buffer}]_{\text{eq}}$ are the concentrations of the compound in plasma and buffer, respectively.

Aqueous solubility

Aqueous solubility in the mediums (a)-(c) was determined by following method:

Whatman mini-UniPrep chambers (Clifton, NJ, USA) containing more than 0.5 mg of compound and 0.5 mL of each medium were shaken overnight (over 8 hours) at room temperature. All samples were filtered through a 0.45 μ m Polyvinylidene Difluoride (PVDF) membrane into the Whatman mini-UniPrep plunger before analysis. The filtrates were assayed by HPLC.

<medium>(a) Simulated gastric fluid with no enzyme (SGN) at pH 1.2: Dissolve 2.0 g of NaCl in 7.0 mL of 10 M HCl and sufficient water to make 1000 mL; (b) Phosphate buffer saline (PBS) at pH 6.5: Dissolve 6.35 g of KH_2PO_4 , 2.84 g of Na_2HPO_4 and 5.50 g of NaCl in sufficient water to make 1000 mL, adjusting the pH to 6.5; (c) 3.94 mg of sodium taurocholate (NaTC) and 1.06 mg of 1-palmitoyl-2-oleyl-L-phosphatidylcholine (POPC) in 1 mL of PBS (pH 6.5).

Estimation of hepatic clearance using the metabolic stability in human hepatocytes

Tested compounds (1 μ M) were incubated statically with hepatocytes from human at 37 °C in a 95 % air/ 5 % CO_2 with target cell density of 0.5×10^6 cells/ml and a total volume of 50 μ L. Incubation was stopped at each time point by the addition of ice-cold acetonitrile (ACN). Aliquots of samples were mixed with 10 % ACN containing an internal standard for LC/MS/MS analysis. After samples were sonicated for 10 minutes, samples were centrifuged at 2,000 rpm for 15 minutes, and then the supernatant was transferred to the other plates for analysis. The compound concentrations in supernatant were measured by LC/MS/MS system.

The disappearance rates of tested compounds were obtained by plotting the common logarithm of the peak area ratio of compounds / internal standard versus time. The slope of the line of best fit through the points yielded the rate of metabolism (k_e). This value was scaled to take hepatocellularity, liver and body weight into account to give an intrinsic clearance value (CL_{int}) in ml/min/kg as illustrated in

Equation 1. Hepatic clearance (CL_h) was predicted from this intrinsic clearance value using the parallel tube model as shown in Equation 2. The predicted clearance divided by the hepatic blood flow (Q_h) afforded the extraction ratio (E_h) (Equation 3).

$$\text{Equation 1: } k_e \times (\text{g liver/kg body weight}) \times (\text{ml incubation/ number of cells in incubation}) \times (\text{cells/g liver})$$

$$\text{Equation 2: } CL_h = Q_h \times \{ 1 - \exp (-CL_{int} / Q_h) \}$$

$$\text{Equation 3: } E_h = CL_h / Q_h$$

Wherein, "gliver weight /kg body weight" is 21, "Cells / g liver" is 1.2×10^8 , "ml incubation/ number of cells in incubation" is 2.0×10^{-6} , and Q_h is 20 ml/min/kg.

Supposing that hepatic metabolism is the main route of drug elimination, systemic exposure (AUC_{po}) after oral administration is calculated using Equation 4.

$$\text{Equation 4 } AUC_{po} = \text{Dose} \times (1 - E_h) / CL_h$$

15 **Method for assaying the compounds phototoxic potential:**

The phototoxic potential was measured in the strict accordance with method described in the OECD Guidelines for the Testing of Chemicals 432 (2002). Chlorpromazine (CPZ) and Sodium n-Dodecyl Sulfate (SDS) were used as positive and negative controls, respectively.

Balb/3T3, clone 31 cells (ATCC, CCL-163) were seeded into 96-wells plates (Nunc, 167008) at a density of 1×10^4 cells/well. Cells were incubated under a standard condition (37 °C, a humidified atmosphere of 95% air and 5% CO₂) within the culture medium-DMEM (GIBCO; cat#11885-084) for 24 hour. Following the incubation, the culture medium-DMEM was discarded and the cells were washed carefully with 150 µl of Earle's Balanced Salt Solution (EBSS; Sigma, Cat#E3024), then added 100 µl solution of the test compound in EBSS or solvent control (EBSS contained 1% dimethylsulphoxide or 1% ethanol). The plate was prepared in duplicate. All the plates were incubated under the standard condition for 60 min in the dark. One of the duplicated plates was used for determination of cytotoxicity (-Irr) and kept at room temperature in the dark for 50 min. For the determination of photocytotoxicity (+Irr), another one was exposed to the sun simulator (UVA irradiance: 1.7mW/cm²; SOL500, Dr. Honle UV Technology, Germany) for 50 min (UVA dose = 5 joules / cm²). Then the solutions were discarded from the two plates and immediately washed with 150 µl of EBSS with care. The cells were further incubated with 150 µl / well of DMED medium for 18 – 22 hr.

After the incubation, the culture medium was discarded, the cells were washed carefully with 150 µl of EBSS and then immediately incubated with 100 µl/well of a 50 µg/ml of neutral red (NR) (3-amino-7-dimethylamino-2-methylphenazine hydrochloride, Kanto Chemical Co., Inc., Japan) in DMEM without serum for 3 hour under the standard condition. After incorporation of neutral red into the cell lysosomes, the NR-DMED medium was discarded and the cells were washed carefully with 150 µl of EBSS. The exact 150 µl of ethanol/acetic acid/water (50:1:49) was added to each well of plate and the extraction was performed for 10 minutes by gently shaking at room temperature. Then optical density (OD) of the NR extract was measured at 540 nm using a spectrophotometer (Plate-reader, POLARstar OPTIMA; BMG Labtechnologies, Germany). The OD values were used to calculate the mean photo effect (MPE)

value using OECD provided software "3T3 NRU Phototox". (Version 2.0, Federal Institute for Risk Assessment, Germany). The results for the control (CPZ and SDS) were used for the quality assurance of the assay.


MPE value < 0.1 was evaluated as "no-phototoxicity"; MPE value ≥ 0.1 and < 0.15 was evaluated as "probable phototoxicity" and MPE value ≥ 0.15 was evaluated as "phototoxicity".

Examples

The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention. Unless stated on otherwise in the following examples, general experimental conditions are as follows: all operations were carried out at room or ambient temperature, that is, in the range of 18-25 °C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure with a bath temperature of up to 60 °C; reactions were monitored by thin layer chromatography (TLC) and reaction times are given for illustration only; melting points (mp) given are uncorrected (polymorphism may result in different melting points); the structure and purity of all isolated compounds were assured by at least one of the following techniques: TLC (Merck silica gel 60 F₂₅₄ precoated TLC plates or Merck NH₂ gel (an amine coated silica gel) F_{254s} precoated TLC plates), mass spectrometry, nuclear magnetic resonance spectra (NMR), infrared absorption spectra (IR) or microanalysis. Yields are given for illustrative purposes only. Flash column chromatography was carried out using Biotage KP-SIL (40-63 μ m), Biotage KP-NH (an amine coated silica gel) (40-75 μ m) or Wako silica gel 300HG (40-60 μ m). Preparative TLC was carried out using Merck silica gel 60 F₂₅₄ precoated TLC plates (0.5 or 1.0 mm thickness). All Mass data was obtained in Low-resolution mass spectral data (ESI) using ZMDTM or ZQTM (Waters) and mass spectrometer. NMR data were determined at 270 MHz (JEOL JNM-LA 270 spectrometer) or 300 MHz (JEOL JNM-LA300 spectrometer) using deuterated chloroform (99.8%) or dimethylsulfoxide (99.9%) as solvent unless indicated otherwise, relative to tetramethylsilane (TMS) as internal standard in parts per million (ppm); conventional abbreviations used are: s = singlet, d = doublet, m = multiplet, dd = doublet of doublet, br.s = broad singlet, etc. IR spectra were measured by a Fourier transform infrared spectrophotometer (Shimazu FTIR-8300). Optical rotations were measured using a JASCO DOP-370 and P-1020 Digital Polarimeter (Japan Spectroscopic CO, Ltd.).

Example 1

8-(3,4-Dihydro-2H-chromen-4-ylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide (example 1-1)



STEP 1: Isopropyl 8-(3,4-dihydro-2H-chromen-4-ylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxyl

ate

To a suspension of isopropyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (8.00 g, 32.3 mmol, WO02/20523), sodium iodide (2.42 g, 16.2 mmol) and potassium carbonate (15.6 g, 113 mmol) in acetone (100 mL) was added a solution of 4-chlorochromane (10.9 g, 64.6 mmol, WO00/78751) in acetone (20 mL) at room temperature and the reaction mixture was stirred at reflux temperature for 24 hours. The reaction mixture was quenched with water and extracted with dichloromethane (80 mL x 2). The combined extracts were washed with brine, dried over magnesium sulfate, and concentrated in vacuum. The residue was purified by column chromatography on silica gel (*n*-hexane : ethyl acetate = 7 : 1 as eluent) to afford the titled compound as a white solid (6.37 g, 52%).

¹H NMR (300 MHz, CDCl₃) δ: 8.06-8.03 (m, 1H), 7.34-7.28 (m, 1H), 7.24-7.17 (m, 1H), 6.93-6.83 (m, 2H), 6.79 (s, 1H), 5.44 (d, *J* = 6.61 Hz, 1H), 5.38-5.23 (m, 1H), 4.89-4.79 (m, 1H), 4.34-4.25 (m, 2H), 2.43 (s, 3H), 2.37 (s, 3H), 2.29-2.20 (m, 2H), 1.41 (d, *J* = 5.87 Hz, 6H) ppm.

MS: 380 (M+H)⁺.

STEP 2: 8-(3,4-Dihydro-2H-chromen-4-ylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid hydrochloride

A mixture of isopropyl 8-(3,4-dihydro-2H-chromen-4-ylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (2.00 g, 5.27 mmol, Step 1), methanol (100 mL), and 2 M sodium hydroxide solution (14.2 mL) was stirred at 60 °C for 5 hours. The reaction mixture was cooled, and water (50 mL) was added to the mixture. The pH was adjusted to pH = 3 by addition of 2 M hydrochloric acid. The mixture was extracted with dichloromethane : methanol = 10 : 1 (50 mL x 2) and ethyl acetate (30 mL). The combined organic layer was washed with brine, dried over sodium sulfate, and evaporated in vacuum to afford the titled compound as a white solid (1.70 g, 86%).

¹H NMR (300 MHz, DMSO-d₆) δ: 8.33 (s, 1H), 7.28-7.20 (m, 3H), 7.05-6.94 (m, 1H), 6.92-6.84 (m, 2H), 5.10-4.99 (m, 1H), 4.36-4.20 (m, 2H), 2.51 (s, 3H), 2.41 (s, 3H), 2.17-2.00 (m, 2H) ppm. (-CO₂H and HCl salt were not observed)

MS: 338 (M + H)⁺, 336 (M - H)⁻.

STEP 3: 8-(3,4-Dihydro-2H-chromen-4-ylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide

To a stirred mixture of 8-(3,4-dihydro-2H-chromen-4-ylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid hydrochloride (1.00 g, 2.68 mmol, Step 2) and dimethylamine hydrochloride (362 mg, 4.44 mmol) in dichloromethane (50 mL) were added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (852 mg, 4.44 mmol), 1-hydroxybenzotriazole hydrate (HOBt) (680 mg, 4.44 mmol), and triethylamine (1.64 mL) at 0 °C. After being stirred at room temperature overnight, the reaction mixture was quenched with water (50 mL). The mixture was extracted with dichloromethane (50 mL x 2) and the combined extracts were washed with brine, dried over sodium sulfate, and evaporated in vacuum. The residue was purified by column chromatography on silica gel eluting with ethyl acetate to afford the titled compound as a white solid (992 mg, 92%).

¹H NMR (300 MHz, CDCl₃) δ: 7.44 (d, *J* = 1.32 Hz, 1H), 7.34-7.14 (m, 2H), 6.91-6.84 (m, 2H), 6.21 (s, 1H), 5.48 (d, *J* = 6.59 Hz, 1H), 4.78-4.72 (m, 1H), 4.34-4.22 (m, 2H), 3.11 (s, 6H), 2.36 (s, 6H), 2.32-2.11 (m,

2H) ppm.

MS: 365 (M + H)⁺.

The fraction-1 (400 mg) and fraction-2 (418 mg) were prepared from racemic
5 8-(3,4-dihydro-2H-chromen-4-ylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide (992 mg) by HPLC as follows.

Resolution condition

Column: CHIRALPAK[®] AD-H (20 mm I.D. x 250 mm, DAICEL)

Mobile phase: *n*-Hexane / Ethanol / Diethylamine (80 / 20 / 0.1)

10 Flow rate: 18.9 mL/min

(-)-8-(3,4-Dihydro-2H-chromen-4-ylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide
(fraction-1) (example 1-2)

NMR: spectrum data were identical with those of the racemate

Optical rotation: $[\alpha]_D^{24} = -13.0^\circ$ (c = 1.00, Methanol)

15 Retention time: 8 min

(+)-8-(3,4-Dihydro-2H-chromen-4-ylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide
(fraction-2) (example 1-3)


NMR: spectrum data were identical with those of the racemate

Optical rotation: $[\alpha]_D^{23} = +13.4^\circ$ (c = 1.00, Methanol)

20 Retention time: 11 min

Example2

8-(3,4-Dihydro-2H-chromen-4-ylamino)-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide (example 2-1)



25

The title compound was prepared in 86% yield (1.11 g) from
8-(3,4-dihydro-2H-chromen-4-ylamino)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylic acid hydrochloride
(1.10 g, 2.94 mmol) and 2-(methylamino)ethanol (367 mg, 4.89 mmol) by the same manner as the
preparation of

30 8-(3,4-dihydro-2H-chromen-4-ylamino)-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide (Step 3 of Example 1).

¹H NMR (300 MHz, CDCl₃) δ: 7.52 (s, 1H), 7.31-7.17 (m, 2H), 6.91-6.84 (m, 2H), 6.25 (s, 1H), 5.51 (d, J = 6.97, 1H), 4.79-4.73 (m, 1H), 4.30-4.26 (m, 2H), 4.01-3.82 (m, 2H), 3.79-3.60 (m, 2H), 3.14 (s, 3H), 2.36 (s, 6H), 2.29-2.17 (m, 2H) ppm. (-OH was not observed)

MS: 395 (M+H)⁺.

The fraction-1 (511 mg) and fraction-2 (532 mg) were prepared from racemic 8-(3,4-dihydro-2*H*-chromen-4-ylamino)-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide (1.11 g) by HPLC as follows.

Resolution condition

Column: CHIRALPAK[®] AD-H (20 mm I.D. x 250 mm, DAICEL)

Mobile phase: *n*-Hexane / Ethanol / Diethylamine (85 / 15 / 0.1)

Flow rate: 18.9 mL/min

- 10 (-)-8-(3,4-Dihydro-2*H*-chromen-4-ylamino)-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide (fraction-1) (example 2-2)

NMR: spectrum data were identical with those of the racemate

Optical rotation: $[\alpha]_D^{23} = -13.6^\circ$ (c = 1.00, Methanol)

Retention time: 10 min

- 15 (+)-8-(3,4-Dihydro-2*H*-chromen-4-ylamino)-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide (fraction-2) (example 2-3)

NMR: spectrum data were identical with those of the racemate


Optical rotation: $[\alpha]_D^{23} = +15.0^\circ$ (c = 1.00, Methanol)

Retention time: 13 min

20

Example 3

8-(3,4-Dihydro-1*H*-isochromen-4-ylamino)-*N*,*N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide (example 3-1)



25 STEP 1: 4-Chloro-3,4-dihydro-1*H*-isochromene

A solution of thionyl chloride (14.3 mL, 196 mmol) in diethyl ether (20 mL) was added to a mixture of 3,4-dihydro-1*H*-isochromen-4-ol (5.89 g, 39.2 mmol, WO04/024081) and pyridine (1.0 mL) in diethyl ether (100 mL). The reaction mixture was stirred at room temperature overnight. After the mixture was evaporated in vacuum, the residue was poured into ice and the mixture was extracted with diethyl ether (50 mL x 2). The combined extracts were washed with brine, dried over magnesium sulfate, and concentrated in vacuum to afford the titled compound as yellow oil (6.55 g, 99%).

30

¹H NMR (270 MHz, CDCl₃) δ: 7.60-7.40 (m, 1H), 7.40-7.20 (m, 2H), 7.10-6.90 (m, 1H), 5.18-5.08 (m, 1H), 4.95-4.72 (m, 2H), 4.35-4.10 (m, 2H) ppm.

STEP 2: Isopropyl 8-(3,4-dihydro-1*H*-isochromen-4-ylamino)-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxylate

xylate

To a suspension of isopropyl 8-amino-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxylate (6.40 g, 25.9 mmol, WO02/20523), sodium iodide (1.95 g, 13.0 mol) and potassium carbonate (7.16 g, 51.8 mmol) in 2-propanol (50 mL) was added dropwise a solution of 4-chloro-3,4-dihydro-1*H*-isochromene (4.37 g, 25.9 mmol, Step 1) in 2-propanol (3.0 mL) at 70 °C and the reaction mixture was stirred at 70 °C overnight. To the mixture, a solution of 4-chloro-3,4-dihydro-1*H*-isochromene (2.19 g, 13.0 mmol) in 2-propanol (1.0 mL) was added and the reaction mixture was stirred at 70 °C for 24 hours. After cooled to room temperature, the mixture was evaporated in vacuum. The residue was treated with water and extracted with dichloromethane (50 mL x 2). The combined extracts were washed with brine, dried over magnesium sulfate, and concentrated in vacuum. The residue was purified by column chromatography on silica gel (*n*-hexane : ethyl acetate = 7 : 1 to 3 : 1 as eluent) to afford the titled compound as a yellow solid (2.04 g, 21%).

¹H NMR (270 MHz, CDCl₃) δ: 8.04 (s, 1H), 7.49-7.41 (m, 1H), 7.32-7.16 (m, 2H), 7.07-7.00 (m, 1H), 6.80 (s, 1H), 5.47 (d, *J* = 9.40 Hz, 1H), 5.36-5.21 (m, 1H), 4.96-4.70 (m, 3H), 4.17-3.97 (m, 2H), 2.42 (s, 3H), 2.36 (s, 3H), 1.40 (d, *J* = 6.61 Hz, 6H) ppm.

MS: 380 (M+H)⁺.

STEP 3: 8-(3,4-Dihydro-1*H*-isochromen-4-ylamino)-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxylic acid hydrochloride

The title compound was prepared in quantitative yield (2.05 g) from isopropyl 8-(3,4-dihydro-1*H*-isochromen-4-ylamino)-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxylate (2.04 g, 5.38 mmol, Step 2) by the same manner as the preparation of 8-(3,4-dihydro-2*H*-chromen-4-ylamino)-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxylic acid hydrochloride (Step 2 of Example 1).

¹H NMR (300 MHz, DMSO-*d*₆) δ: 8.19 (s, 1H), 7.42-7.08 (m, 4H), 6.97 (br.s, 1H), 6.15-5.89 (m, 1H), 5.04-4.89 (m, 1H), 4.89-4.57 (m, 2H), 4.06-3.89 (m, 2H), 2.43 (s, 3H), 2.31 (s, 3H) ppm. (-CO₂H and HCl salt were not observed)

STEP 4: 8-(3,4-Dihydro-1*H*-isochromen-4-ylamino)-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide

The title compound was prepared in 59% yield (46 mg) from 8-(3,4-dihydro-1*H*-isochromen-4-ylamino)-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxylic acid hydrochloride (80 mg, 0.22 mmol, Step 3) and dimethylamine hydrochloride (65 mg, 0.36 mmol) by the same manner as the preparation of 8-(3,4-dihydro-2*H*-chromen-4-ylamino)-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide (Step 3 of Example 1).

¹H NMR (270 MHz, DMSO-*d*₆) δ: 7.61 (s, 1H), 7.43-7.03 (m, 4H), 6.40 (s, 1H), 5.69 (d, *J* = 9.99 Hz, 1H), 5.07-4.88 (m, 1H), 4.88-4.61 (m, 2H), 4.09-3.83 (m, 2H), 2.98 (s, 6H), 2.34 (s, 3H), 2.24 (s, 3H) ppm.

MS: 365 (M+H)⁺.

The fraction-1 (6.4 mg) and fraction-2 (9.3 mg) were prepared from racemic 8-(3,4-dihydro-1*H*-isochromen-4-ylamino)-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide (21

mg) by HPLC as follows.

Resolution condition

Column: CHIRALPAK® AD-H (20 mm I.D. x 250 mm, DAICEL)

Mobile phase: *n*-Hexane / Ethanol / Diethylamine (85 / 15 / 0.1)

Flow rate: 18.9 mL/min

(-)-8-(3,4-Dihydro-1*H*-isochromen-4-ylamino)-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide (fraction-1) (example 3-2)

NMR: spectrum data were identical with those of the racemate

Optical rotation: $[\alpha]_D^{24} = -19.4^\circ$ (*c* = 1.00, Methanol)

Retention time: 14 min

(+)-8-(3,4-Dihydro-1*H*-isochromen-4-ylamino)-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide (fraction-2) (example 3-3)


NMR: spectrum data were identical with those of the racemate

Optical rotation: $[\alpha]_D^{24} = +20.4^\circ$ (*c* = 1.00, Methanol)

Retention time: 19 min

Example 4

8-(3,4-Dihydro-1*H*-isochromen-4-ylamino)-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide (example 4-1)



A mixture of isopropyl 8-(3,4-dihydro-1*H*-isochromen-4-ylamino)-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxylate (270 mg, 0.71 mmol, Step 2 of Example 3), 2-(methylamino)ethanol (530 mg, 7.1 mmol) and sodium cyanide (2.0 mg, 0.04 mmol) was refluxed in tetrahydrofuran (2.0 mL) for 14 hours. After cooled to room temperature, the solvent was evaporated in vacuum. The residue was purified by column chromatography on NH gel (dichloromethane to dichloromethane : methanol = 40 : 1 as eluent) to afford the titled compound as a white solid (100 mg, 37%).

¹H NMR (300 MHz, CDCl₃) δ : 7.55-7.49 (m, 1H), 7.44 (d, *J* = 6.60 Hz, 1H), 7.34-7.16 (m, 3H), 7.04 (d, *J* = 6.60 Hz, 1H), 6.28 (br.s, 1H), 5.65-5.42 (m, 1H), 4.94-4.69 (m, 3H), 4.10-4.01 (m, 2H), 3.97-3.82 (m, 2H), 3.80-3.61 (m, 2H), 3.14 (s, 3H), 2.36 (s, 6H) ppm.

MS: 395 (M+H)⁺.

The fraction-1 (22 mg) and fraction-2 (20 mg) were prepared from racemic 8-(3,4-dihydro-1*H*-isochromen-4-ylamino)-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide (63 mg) by HPLC as follows.

Resolution condition

Column: CHIRALPAK® AD-H (20 mm I.D. x 250 mm, DAICEL)

Mobile phase: *n*-Hexane / Ethanol / Diethylamine (80 / 20 / 0.1)

Flow rate: 18.9 mL/min

- 5 (-)-8-(3,4-Dihydro-1*H*-isochromen-4-ylamino)-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide (fraction-1) (example 4-2)

NMR: spectrum data were identical with those of the racemate

Optical rotation: $[\alpha]_D^{23} = -39.8^\circ$ (*c* = 1.00, Methanol)

Retention time: 11 min

- 10 (+)-8-(3,4-Dihydro-1*H*-isochromen-4-ylamino)-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide (fraction-2) (example 4-3)


NMR: spectrum data were identical with those of the racemate

Optical rotation: $[\alpha]_D^{24} = +40.8^\circ$ (*c* = 1.00, Methanol)

Retention time: 12 min

15 **Example 5**

***N*-(2-Hydroxyethyl)-*N*,2,3-trimethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide (example 5-1)**



20 **STEP 1: 4-Chloro-5-methylchromane**

A solution of thionyl chloride (6.0 mL, 83 mmol) in diethyl ether (6 mL) was added to a mixture of 5-methylchroman-4-ol (2.7 g, 17 mmol, *Tetrahedron Asym.*, **1997**, 8, 3059.) and pyridine (0.4 mL) in diethyl ether (30 mL). The reaction mixture was stirred at room temperature for 8 hours. After the mixture was evaporated in vacuum, the residue was poured into ice and the mixture was extracted with ethyl acetate (50 mL x 2). The combined extracts were washed with brine, dried over magnesium sulfate, and concentrated in vacuum to afford the titled compound as yellow oil (3.2 g, quantitative yield).

¹H NMR (300 MHz, CDCl₃) δ : 7.21-7.04 (m, 1H), 6.86-6.62 (m, 2H), 5.36-5.17 (m, 1H), 4.59-4.43 (m, 1H), 4.43-4.30 (m, 1H), 2.41 (s, 3H), 2.57-2.24 (m, 2H) ppm.

30 **STEP 2: Methyl 2,3-dimethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxylate**

A mixture of 4-chloro-5-methylchromane (3.2 g, 16 mmol, Step 1), methyl 8-amino-2,3-dimethylimidazo[1,2-*a*]pyridine-6-carboxylate (2.4 g, 11 mmol, WO02/020523), sodium iodide (0.83 g, 5.5 mol) and potassium carbonate (5.3 g, 38 mmol) in acetone (100 mL) was stirred at reflux for 2

days. After cooled to room temperature, the mixture was quenched with water (50 mL) and extracted with dichloromethane (100 mL x 2). The combined extracts were washed with brine, dried over magnesium sulfate, and concentrated in vacuum. The residue was purified by column chromatography on silica gel (*n*-hexane : ethyl acetate = 5 : 1 as eluent) to afford the titled compound as a white solid (3.0 g, 74%).

- 5 ¹H NMR (300 MHz, CDCl₃) δ: 8.09 (s, 1H), 7.18-7.06 (m, 1H), 6.83-6.68 (m, 3H), 5.36-5.25 (m, 1H), 4.79-4.68 (m, 1H), 4.32-4.17 (m, 2H), 3.96 (s, 3H), 2.41 (s, 3H), 2.36 (s, 3H), 2.22 (s, 3H), 2.48-1.98 (m, 2H) ppm.

MS: 366 (M+H)⁺.

10 STEP 3: 2,3-Dimethyl-8-[(5-methyl-3,4-dihydro-2H-chromen-4-yl)amino]imidazo[1,2-a]pyridine-6-carboxylic acid

To a mixture of methyl

2,3-dimethyl-8-[(5-methyl-3,4-dihydro-2H-chromen-4-yl)amino]imidazo[1,2-a]pyridine-6-carboxylate (3.0 g, 8.2 mmol, Step 2) in methanol (30 mL)-tetrahydrofuran (15 mL) was added 2 M sodium hydroxide solution (12 mL) and the reaction mixture was stirred at 50 °C for 2 hours. After cooled to room temperature, the mixture was evaporated in vacuum. The residue was treated with water (10 ml) and the pH was adjusted to pH = 6 by addition of 2M hydrochloric acid. The precipitate was collected by filtration and washed with water (5 mL), acetone (5 mL), and dried to afford the titled compound as a white solid (3.6 g, quantitative yield).

- 15 ¹H NMR (300 MHz, DMSO-d₆) δ: 8.08 (s, 1H), 7.21-7.03 (m, 1H), 6.83-6.64 (m, 3H), 5.56 (d, *J* = 7.34 Hz, 1H), 4.86-4.73 (m, 1H), 4.31-4.01 (m, 2H), 2.39 (s, 3H), 2.25 (s, 3H), 2.14 (s, 3H), 2.45-1.86 (m, 2H) ppm. (-CO₂H was not observed)

MS: 352 (M+H)⁺.

25 STEP 4: N-(2-Hydroxyethyl)-N,2,3-trimethyl-8-[(5-methyl-3,4-dihydro-2H-chromen-4-yl)amino]imidazo[1,2-a]pyridine-6-carboxamide

To a stirred mixture of

2,3-dimethyl-8-[(5-methyl-3,4-dihydro-2H-chromen-4-yl)amino]imidazo[1,2-a]pyridine-6-carboxylic acid (2.7 g, 7.7 mmol, Step 3) and 2-(methylamino)ethanol (1.1 g, 15 mmol) in dichloromethane (16 mL) were added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) (2.9 g, 15 mmol) and 1-hydroxybenzotriazole hydrate (HOBt) (2.1 g, 15 mmol) at 0 °C and the reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with saturated sodium hydrogencarbonate (30 mL). The mixture was extracted with dichloromethane (50 mL x 2) and the combined extracts were washed with brine, dried over sodium sulfate, and evaporated in vacuum. The residue was purified by column chromatography on silica gel (dichloromethane : methanol = 30 : 1 as eluent) to afford the titled compound as a white solid (2.0 g, 63%).

¹H NMR (270 MHz, CDCl₃) δ: 7.52 (s, 1H), 7.17-7.06 (m, 1H), 6.82-6.65 (m, 2H), 6.30 (s, 1H), 5.38 (d, *J* = 5.93 Hz, 1H), 4.73-4.59 (m, 1H), 4.34-4.15 (m, 2H), 4.03-3.84 (m, 2H), 3.84-3.62 (m, 2H), 3.18 (s, 3H), 2.36 (s, 3H), 2.35 (s, 3H), 2.22 (s, 3H), 2.30-1.96 (m, 2H) ppm. (-OH was not observed)

- 40 MS: 409 (M+H)⁺.

IR (KBr) ν_{\max} : 3443, 1616, 1557, 1407, 1254, 1095, 1056, 783, 748 cm^{-1} .

The fraction-1 (72 mg) and fraction-2 (70 mg) were prepared from racemic *N*-(2-hydroxyethyl)-*N*,2,3-trimethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide (180 mg) by HPLC as follows.

5 Resolution condition

Column: CHIRALPAK® OD-H (20 mm I.D. x 250 mm, DAICEL)

Mobile phase: *n*-Hexane / Ethanol / Diethylamine (90 / 10 / 0.1)

Flow rate: 18.9 mL/min

(-)-*N*-(2-Hydroxyethyl)-*N*,2,3-trimethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyr

10 dine-6-carboxamide (fraction-1) (example 5-2)

NMR: spectrum data were identical with those of the racemate

Optical rotation: $[\alpha]_{\text{D}}^{24} = -6.2^{\circ}$ ($c = 1.00$, Methanol)

Retention time: 11 min

The absolute configuration of the compound of example 5-2 was determined as (*S*)-form by single

15 crystal X-Ray analysis.

(+)-*N*-(2-Hydroxyethyl)-*N*,2,3-trimethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyr
idine-6-carboxamide (fraction-2) (example 5-3)

NMR: spectrum data were identical with those of the racemate


20 Optical rotation: $[\alpha]_{\text{D}}^{24} = +5.8^{\circ}$ ($c = 1.00$, Methanol)





Retention time: 13 min




The absolute configuration of the compound of example 5-3 was determined as (*R*)-form by single
crystal X-Ray analysis.





25 Following **Examples 6 to 19** were prepared according to the procedure described in Step 1-3 of Example 1.



^1H -NMR was measured with using CDCl_3 .

<p>Example 6</p> 	<p>8-[(7-Fluoro-3,4-dihydro-2<i>H</i>-chromen-4-yl)amino]-<i>N</i>,<i>N</i>,2,3-tetramethylimidazo[1,2-<i>a</i>]pyridine-6-carboxamide (example 6-1)</p> <p>white solid</p> <p>^1H-NMR (300 MHz) δ: 7.45 (s, 1H), 7.36-7.16 (m, 1H), 6.69-6.52 (m, 2H), 6.22 (s, 1H), 5.43 (d, $J = 6.6$ Hz, 1H), 4.80-4.67 (m, 1H), 4.37-4.20 (m, 2H), 3.12 (s, 6H), 2.37 (s, 6H), 2.33-2.05 (m, 2H) ppm.</p> <p>MS m/z: 383 ($M + H$)$^+$.</p> <p>Resolution condition</p> <p>Column: CHIRALPAK® AD-H (20 mm I.D. x 250 mm, DAICEL)</p> <p>Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (80 / 20 / 0.1)</p> <p>Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 6-2): optical rotation: $[\alpha]_{\text{D}}^{24} = -12.3^{\circ}$ ($c = 1.00$, Methanol), retention time: 8 min</p> <p>(+)-isomer (example 6-3): optical rotation: $[\alpha]_{\text{D}}^{25} = +10.6^{\circ}$ ($c = 1.00$, Methanol), retention time: 12 min</p>
<p>Example 7</p>	<p>8-[(7-Fluoro-3,4-dihydro-2<i>H</i>-chromen-4-yl)amino]-<i>N</i>-(2-hydroxyethyl)-<i>N</i>,2,3-trimethylimidazo[1,2-<i>a</i>]pyridine-6-carboxamide (example 7-1)</p>

	<p>white solid</p> <p>¹H-NMR (270 MHz, CDCl₃) δ: 7.52 (s, 1H), 7.38-7.14 (m, 1H), 6.70-6.49 (m, 2H), 6.25 (s, 1H), 5.45 (d, <i>J</i> = 6.6 Hz, 1H), 4.80-4.65 (m, 1H), 4.38-4.19 (m, 2H), 4.01-3.82 (m, 2H), 3.82-3.61 (m, 2H), 3.15 (s, 3H), 2.37 (s, 6H), 2.45-2.01 (m, 2H) ppm. (OH was not observed)</p> <p>MS <i>m/z</i>: 411 (<i>M</i> - H)⁻.</p> <p>Resolution condition Column: CHIRALPAK[®] AS-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (90 / 10 / 0.1) Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 7-2): optical rotation: [α]_D²⁴ = -10.5 ° (<i>c</i> = 1.00, Methanol), retention time: 8 min</p> <p>(+)-isomer (example 7-3): optical rotation: [α]_D²⁴ = +12.2 ° (<i>c</i> = 1.00, Methanol), retention time: 10 min</p>
<p>Example 8</p>	<p>8-[(5,7-Difluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide (example 8-1)</p>
	<p>white solid</p> <p>¹H-NMR (270 MHz, CDCl₃) δ: 7.45 (d, <i>J</i> = 1.3 Hz, 1H), 6.45-6.35 (m, 2H), 6.26 (s, 1H), 5.39 (d, <i>J</i> = 5.9 Hz, 1H), 4.88-4.83 (m, 1H), 4.32-4.28 (m, 2H), 3.13 (s, 6H), 2.36 (s, 6H), 2.29-2.23 (m, 1H), 2.06-1.93 (m, 1H) ppm.</p> <p>MS <i>m/z</i>: 401 (<i>M</i> + H)⁺.</p> <p>Resolution condition Column: CHIRALCEL[®] OD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (90 / 10 / 0.1) Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 8-2): optical rotation: [α]_D²⁴ = -50.4 ° (<i>c</i> = 1.00, Methanol), retention time: 10 min</p> <p>(+)-isomer (example 8-3): optical rotation: [α]_D²⁴ = +47.9 ° (<i>c</i> = 1.00, Methanol), retention time: 13 min</p>
<p>Example 9</p>	<p>8-[(5,7-Difluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide (example 9-1)</p>
	<p>white solid</p> <p>¹H-NMR (270 MHz, CDCl₃) δ: 7.53 (s, 1H), 6.51-6.23 (m, 2H), 6.30 (s, 1H), 5.38 (d, <i>J</i> = 5.9 Hz, 1H), 4.95-4.79 (m, 1H), 4.39-4.22 (m, 2H), 4.02-3.83 (m, 2H), 3.80-3.62 (m, 2H), 3.18 (s, 3H), 2.36 (s, 6H), 2.33-2.19 (m, 1H), 2.15-1.91 (m, 1H) ppm. (OH was not observed)</p> <p>MS <i>m/z</i>: 431 (<i>M</i> + H)⁺.</p> <p>Resolution condition Column: CHIRALPAK[®] OD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (90 / 10 / 0.1) Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 9-2): optical rotation: [α]_D²³ = -44.8 ° (<i>c</i> = 0.50, Methanol), retention time: 11 min</p> <p>(+)-isomer (example 9-3): optical rotation: [α]_D²³ = +39.3 ° (<i>c</i> = 0.50, Methanol), retention time: 13 min</p>
<p>Example 10</p>	<p>8-[(5-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide (example 10-1)</p>
	<p>white solid</p> <p>¹H-NMR (270 MHz, CDCl₃) δ: 7.45 (s, 1H), 7.25-7.12 (m, 1H), 6.69 (d, <i>J</i> = 8.1 Hz, 1H), 6.67-6.57 (m, 1H), 6.27 (s, 1H), 5.40 (d, <i>J</i> = 5.4 Hz, 1H), 4.95-4.85 (m, 1H), 4.40-4.25 (m, 2H), 3.13 (s, 6H), 2.36 (s, 6H), 2.35-1.90 (m, 2H) ppm.</p> <p>MS <i>m/z</i>: 383 (<i>M</i> + H)⁺.</p> <p>Resolution condition Column: CHIRALCEL[®] OD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (75 / 25 / 0.1) Flow rate: 20.0 mL/min</p> <p>(-)-isomer (example 10-2): optical rotation: [α]_D²⁴ = -51.1 ° (<i>c</i> = 1.00, Methanol), retention time: 5 min</p>

	(+)-isomer (example 10-3): optical rotation: $[\alpha]_D^{24} = +51.7^\circ$ (c = 1.00, Methanol), retention time: 8 min
Example 11	8-[(5-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide (example 11-1)
	white solid $^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 7.52 (s, 1H), 7.18 (dd, $J = 8.1, 6.6$ Hz, 1H), 6.68 (d, $J = 8.1$ Hz, 1H), 6.66-6.56 (m, 1H), 6.31 (s, 1H), 5.42 (d, $J = 5.9$ Hz, 1H), 4.99-4.85 (m, 1H), 4.38-4.22 (m, 2H), 4.03-3.82 (m, 2H), 3.81-3.63 (m, 2H), 3.18 (s, 3H), 2.36 (s, 6H), 2.32-2.19 (m, 1H), 2.12-1.94 (m, 1H) ppm. (OH was not observed) MS m/z: 413 ($\text{M} + \text{H}$) ⁺ . Resolution condition Column: CHIRALCEL [®] AD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i> -Hexane / Ethanol / Diethylamine (90 / 10 / 0.1) Flow rate: 18.9 mL/min (-)-isomer (example 11-2): optical rotation: $[\alpha]_D^{24} = -49.9^\circ$ (c = 0.50, Methanol), retention time: 12 min (+)-isomer (example 11-3): optical rotation: $[\alpha]_D^{24} = +41.2^\circ$ (c = 0.50, Methanol), retention time: 16 min
Example 12	8-[(6-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide (example 12-1)
	white solid $^1\text{H-NMR}$ (270 MHz, CDCl_3) δ : 7.48-7.43 (m, 1H), 7.03 (dd, $J = 9.2, 3.3$ Hz, 1H), 6.98-6.86 (m, 1H), 6.81 (dd, $J = 9.2, 4.6$ Hz, 1H), 6.20 (s, 1H), 5.48 (d, $J = 7.9$ Hz, 1H), 4.81-4.68 (m, 1H), 4.33-4.18 (m, 2H), 3.10 (s, 6H), 2.37 (s, 6H), 2.30-2.12 (m, 2H) ppm. MS m/z: 383 ($\text{M} + \text{H}$) ⁺ . Resolution condition Column: CHIRALCEL [®] OD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i> -Hexane / Ethanol / Diethylamine (80 / 20 / 0.1) Flow rate: 18.9 mL/min (-)-isomer (example 12-2): optical rotation: $[\alpha]_D^{24} = -3.4^\circ$ (c = 1.00, Methanol), retention time: 9 min (+)-isomer (example 12-3): optical rotation: $[\alpha]_D^{24} = +2.4^\circ$ (c = 1.00, Methanol), retention time: 6 min
Example 13	8-[(6-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide (example 13-1)
	white solid $^1\text{H-NMR}$ (300MHz, CDCl_3) δ : 7.53 (s, 1H), 7.03 (dd, $J = 8.1, 2.9$ Hz, 1H), 6.95-6.88 (m, 1H), 6.83-6.78 (m, 1H), 6.24 (s, 1H), 5.52 (d, $J = 6.5$ Hz, 1H), 4.90-4.70 (m, 1H), 4.32-4.21 (m, 2H), 3.98-3.83 (m, 2H), 3.79-3.65 (m, 2H), 3.14 (s, 3H), 2.37 (s, 6H), 2.27-2.13 (m, 2H) ppm. (OH was not observed) MS m/z: 413 ($\text{M} + \text{H}$) ⁺ . Resolution condition Column: CHIRALCEL [®] OD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i> -Hexane / Ethanol / Diethylamine (92 / 10 / 0.1) Flow rate: 18.9 mL/min (-)-isomer (example 13-2): optical rotation: $[\alpha]_D^{24} = -7.0^\circ$ (c = 1.00, Methanol), retention time: 17 min (+)-isomer (example 13-3): optical rotation: $[\alpha]_D^{24} = +5.2^\circ$ (c = 1.00, Methanol), retention time: 13 min
Example 14	8-[(8-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide (example 14-1)

	<p>white solid</p> <p>¹H-NMR (300MHz, CDCl₃) δ: 7.45 (s, 1H), 7.10-6.99 (m, 2H), 6.84-6.77 (m, 1H), 6.23 (s, 1H), 5.60 (d, J = 7.3 Hz, 1H), 4.82-4.77 (m, 1H), 4.44-4.31 (m, 2H), 3.11 (s, 6H), 2.37 (s, 6H), 2.34-2.13 (m, 2H) ppm.</p> <p>MS m/z: 383 (M + H)⁺.</p> <p>Resolution condition Column: CHIRALPAK[®] AD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (80 / 20 / 0.1) Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 14-2): optical rotation: [α]_D²⁴ = -13.8 ° (c = 0.30, Methanol), retention time: 9 min</p> <p>(+)-isomer (example 14-3): optical rotation: [α]_D²⁴ = +9.3 ° (c = 0.30, Methanol), retention time: 13 min</p>
<p>Example 15</p> 	<p>8-[(8-Fluoro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide (example 15-1)</p> <p>white solid</p> <p>¹H-NMR (270 MHz, CDCl₃) δ: 7.54 (s, 1H), 7.10-6.98 (m, 2H), 6.84-6.77 (m, 1H), 6.27 (s, 1H), 5.56 (d, J = 7.3 Hz, 1H), 4.82-4.76 (m, 1H), 4.43-4.31 (m, 2H), 4.01-3.84 (m, 2H), 3.76-3.65 (m, 2H), 3.15 (s, 3H), 2.36 (s, 6H), 2.32-2.20 (m, 2H) ppm. (OH was not observed)</p> <p>MS m/z 413: (M + H)⁺.</p> <p>Resolution condition Column: CHIRALPAK[®] AD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (80 / 20 / 0.1) Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 15-2): optical rotation: [α]_D²⁴ = -8.4 ° (c = 1.00, Methanol), retention time: 8 min</p> <p>(+)-isomer (example 15-3): optical rotation: [α]_D²⁴ = +6.7 ° (c = 1.00, Methanol), retention time: 11 min</p>
<p>Example 16</p> 	<p>N-(2-Hydroxyethyl)-N,2,3-trimethyl-8-[(7-methyl-3,4-dihydro-2H-chromen-4-yl)amino]imidazo[1,2-a]pyridine-6-carboxamide (example 16-1)</p> <p>white solid</p> <p>¹H-NMR (300 MHz, CDCl₃) δ: 7.52 (s, 1H), 7.17 (d, J = 7.3 Hz, 1H), 6.77-6.61 (m, 2H), 6.24 (s, 1H), 5.48 (d, J = 7.3 Hz, 1H), 4.78-4.66 (m, 1H), 4.29-4.20 (m, 2H), 4.00-3.82 (m, 2H), 3.82-3.61 (m, 2H), 3.15 (s, 3H), 2.36 (s, 6H), 2.30 (s, 3H), 2.42-2.09 (m, 2H) ppm. (OH was not observed)</p> <p>MS m/z: 409 (M + H)⁺.</p> <p>Resolution condition Column: CHIRALPAK[®] AD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (87 / 13 / 0.1) Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 16-2): optical rotation: [α]_D²⁴ = -12.5 ° (c = 1.00, Methanol), retention time: 13 min</p> <p>(+)-isomer (example 16-3): optical rotation: [α]_D²⁴ = +11.7 ° (c = 1.00, Methanol), retention time: 15 min</p>
<p>Example 17</p> 	<p>N,N,2,3-Tetramethyl-8-[(5-methyl-3,4-dihydro-2H-chromen-4-yl)amino]imidazo[1,2-a]pyridine-6-carboxamide (example 17-1)</p> <p>white solid</p> <p>¹H-NMR (300 MHz, CDCl₃) δ: 7.45 (s, 1H), 7.17-7.07 (m, 1H), 6.80-6.69 (m, 2H), 6.26 (s, 1H), 5.44-5.27 (m, 1H), 4.73-4.59 (m, 1H), 4.36-4.15 (m, 2H), 3.14 (s, 6H), 2.36 (s, 3H), 2.35 (s, 3H), 2.21 (s, 3H), 2.31-1.95 (m, 2H) ppm.</p> <p>MS m/z: 379 (M + H)⁺.</p> <p>Resolution condition Column: CHIRALCEL[®] AD-H (20 mm I.D. x 250 mm, DAICEL) Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (75 / 25 / 0.1) Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 17-2): optical rotation: [α]_D²⁴ = -4.6 ° (c = 1.00, Methanol), retention time: 5 min</p>


	(+)-isomer (example 17-3): optical rotation: $[\alpha]_D^{24} = +4.7^\circ$ (c = 1.00, Methanol), retention time: 9 min
Example 18	8-[(5-Chloro-3,4-dihydro-2H-chromen-4-yl)amino]-N,N,2,3-tetramethylimidazo[1,2-a]pyridine-6-carboxamide (example 18-1)
	<p>white solid</p> <p>$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ: 7.46 (s, 1H), 7.36-7.17 (m, 2H), 6.89-6.76 (m, 1H), 6.22 (s, 1H), 5.54-5.40 (m, 1H), 4.87-4.70 (m, 1H), 4.52-4.32 (m, 2H), 3.11 (s, 6H), 2.37 (s, 6H), 2.51-2.05 (m, 2H) ppm.</p> <p>MS m/z: 399 (M + H)$^+$.</p> <p>Resolution condition</p> <p>Column: CHIRALPAK$^{\text{®}}$ AD-H (20 mm I.D. x 250 mm, DAICEL)</p> <p>Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (85 / 15 / 0.1)</p> <p>Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 18-2): optical rotation: $[\alpha]_D^{24} = -40.8^\circ$ (c = 1.00, Methanol), retention time: 15 min</p> <p>(+)-isomer (example 18-3): optical rotation: $[\alpha]_D^{24} = +43.1^\circ$ (c = 1.00, Methanol), retention time: 20 min</p>
Example 19	8-[(5-Chloro-3,4-dihydro-2H-chromen-4-yl)amino]-N-(2-hydroxyethyl)-N,2,3-trimethylimidazo[1,2-a]pyridine-6-carboxamide (example 19-1)
	<p>white solid</p> <p>$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ: 7.54 (s, 1H), 7.38-7.18 (m, 2H), 6.90-6.75 (m, 1H), 6.26 (s, 1H), 5.47 (d, J = 6.6 Hz, 1H), 4.88-4.71 (m, 1H), 4.50-4.30 (m, 2H), 4.04-3.81 (m, 2H), 3.81-3.60 (m, 2H), 3.14 (s, 3H), 2.36 (s, 6H), 2.46-2.12 (m, 2H) ppm. (OH was not observed)</p> <p>MS m/z: 429 (M + H)$^+$.</p> <p>Resolution condition</p> <p>Column: CHIRALPAK$^{\text{®}}$ AD-H (20 mm I.D. x 250 mm, DAICEL)</p> <p>Mobile phase: <i>n</i>-Hexane / Ethanol / Diethylamine (85 / 15 / 0.1)</p> <p>Flow rate: 18.9 mL/min</p> <p>(-)-isomer (example 19-2): optical rotation: $[\alpha]_D^{24} = -36.4^\circ$ (c = 1.00, Methanol), retention time: 14 min</p> <p>(+)-isomer (example 19-3): optical rotation: $[\alpha]_D^{24} = +36.6^\circ$ (c = 1.00, Methanol), retention time: 17 min</p>

All publications, including but not limited to, issued patents, patent applications, and journal articles, cited in this application are each herein incorporated by reference in their entirety.

Although the invention has been described above with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications could be made without departing from the spirit of the invention.

CLAIMS

1. A compound of the formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

- 5 -A-B- represents -O-CH₂-, -S-CH₂-, -CH₂-O- or -CH₂-S-;
 R¹ represents a C₁-C₆ alkyl group being unsubstituted or substituted with 1 to 2 substituents
 independently selected from the group consisting of a hydroxy group, a moiety convertible in vivo into a
 hydroxy group and a C₁-C₆ alkoxy group;
 R² represents a C₁-C₆ alkyl group;
- 10 R³ represents a C₁-C₆ alkyl group, C₃-C₇ cycloalkyl group or C₃-C₇ cycloalkyl C₁-C₆ alkyl group;
 R⁴ represents a C₁-C₆ alkyl group being unsubstituted or substituted with 1 to 3 substituents
 independently selected from the group consisting of a halogen atom, a hydroxy group, a moiety
 convertible in vivo into a hydroxy group and a C₁-C₆ alkoxy group; and
 R⁵, R⁶, R⁷ and R⁸ independently represent a hydrogen atom, a halogen atom or a C₁-C₆ alkyl group.
- 15
2. The compound or the pharmaceutically acceptable salt, as claimed in claim 1, wherein
 A-B- is -O-CH₂-, or -CH₂-O-;
 R¹, R² and R³ are independently a C₁-C₆ alkyl group;
 R⁴ is a C₁-C₆ alkyl group being unsubstituted or substituted with 1 substituent selected from the group
 consisting of a hydroxy group and a C₁-C₆ alkoxy group;
- 20 R⁵ is a hydrogen atom, a fluorine atom or a C₁-C₆ alkyl group;
 R⁷ is a hydrogen atom, a halogen atom or a C₁-C₆ alkyl group; and
 R⁶ and R⁸ are independently a hydrogen atom, a halogen atom or a C₁-C₆ alkyl group.
- 25
3. The compound or the pharmaceutically acceptable salt, as claimed in claim 1, wherein
 -A-B- is -CH₂-O-;
 R¹, R² and R³ are each methyl group;
 R⁴ is a C₁-C₂ alkyl group being unsubstituted or substituted with a hydroxy group;
 R⁵ and R⁷ are independently a hydrogen atom or methyl group; and
- 30 R⁶ and R⁸ are each hydrogen atom.

4. The compound of claim 1, which is selected from:

- (-)-8-(3,4-Dihydro-2*H*-chromen-4-ylamino)-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(+)-8-(3,4-Dihydro-2*H*-chromen-4-ylamino)-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(+)-8-(3,4-Dihydro-2*H*-chromen-4-ylamino)-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide;
- 5 (+)-*N*-(2-Hydroxyethyl)-*N*,2,3-trimethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide;
(-)-8-[(7-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(-)-8-[(7-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide;
- 10 (+)-8-[(7-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(-)-8-[(5,7-Difluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
- 15 (+)-8-[(5,7-Difluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(+)-8-[(5,7-Difluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(-)-8-[(5-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
- 20 (+)-8-[(5-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(-)-8-[(5-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide;
- 25 (+)-8-[(5-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(-)-8-[(6-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(+)-8-[(6-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N*-(2-hydroxyethyl)-*N*,2,3-trimethylimidazo[1,2-*a*]pyridine-6-carboxamide;
- 30 (+)-8-[(8-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(-)-8-[(8-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
(+)-8-[(8-Fluoro-3,4-dihydro-2*H*-chromen-4-yl)amino]-*N,N*,2,3-tetramethylimidazo[1,2-*a*]pyridine-6-carboxamide;
- 35 (+)-*N*-(2-Hydroxyethyl)-*N*,2,3-trimethyl-8-[(7-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide;
(+)-*N*-(2-Hydroxyethyl)-*N*,2,3-trimethyl-8-[(7-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide;
(-)-*N,N*,2,3-Tetramethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide; and
- 40

(+)-*N,N*,2,3-Tetramethyl-8-[(5-methyl-3,4-dihydro-2*H*-chromen-4-yl)amino]imidazo[1,2-*a*]pyridine-6-carboxamide;
or a pharmaceutically acceptable salt thereof.

5 5. A pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 4, and a pharmaceutically acceptable carrier.

6. The pharmaceutical composition as claimed in claim 5 further comprising other pharmacologically active agent(s).

10

7. A method for the treatment of a condition mediated by acid pump inhibitory activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 4.

15

8. The method as claimed in claim 7, wherein said condition is gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of *Helicobacter pylori*, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

20

9. A use of the compound of formula (I) or the pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 4, for the manufacture of a medicament for the treatment of a condition mediated by acid pump inhibitory activity.

25

10. The use as claimed in claim 9, wherein said condition is gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of *Helicobacter pylori*, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

30

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2005/003758

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K31/437 C07D471/04 A61P1/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/046144 A (ALTANA PHARMA AG; BUHR, WILM; SENN-BILFINGER, JOERG; ZIMMERMANN, PETER) 3 June 2004 (2004-06-03) claims 1,10	1-10
A	WO 03/018582 A (ASTRAZENECA AB; AMIN, KOSRAT; DAHLSTROEM, MIKAEL; NORDBERG, PETER; STA) 6 March 2003 (2003-03-06) claims 1,13	1-10
A	WO 99/55706 A (ASTRA AKTIEBOLAG; AMIN, KOSRAT; DAHLSTROEM, MICHAEL; NORDBERG, PETER;) 4 November 1999 (1999-11-04) cited in the application claims 1,13	1-10

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 March 2006

Date of mailing of the international search report

27/03/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bérillon, L

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2005/003758

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 7, 8
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 7 and 8 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2005/003758

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2004046144	A	03-06-2004	AU 2003288071 A1	15-06-2004
			BR 0316201 A	04-10-2005
			CA 2506027 A1	03-06-2004
			CN 1708497 A	14-12-2005
			ZA 200503224 A	22-11-2005
WO 03018582	A	06-03-2003	BR 0211846 A	08-09-2004
			CA 2456350 A1	06-03-2003
			CN 1543464 A	03-11-2004
			EP 1421083 A1	26-05-2004
			HU 0401350 A2	28-12-2004
			JP 2005501870 T	20-01-2005
			MX PA04001402 A	27-05-2004
			NO 20040760 A	20-02-2004
			NZ 531110 A	28-10-2005
			US 2004220209 A1	04-11-2004
			ZA 200401114 A	22-06-2005
WO 9955706	A	04-11-1999	AT 307130 T	15-11-2005
			AT 312101 T	15-12-2005
			AU 769108 B2	15-01-2004
			AU 4300699 A	16-11-1999
			AU 769190 B2	22-01-2004
			AU 4300799 A	16-11-1999
			BR 9909995 A	26-12-2000
			BR 9909996 A	26-12-2000
			CA 2329921 A1	04-11-1999
			CA 2329922 A1	04-11-1999
			CN 1306533 A	01-08-2001
			CN 1307577 A	08-08-2001
			CZ 20003981 A3	14-03-2001
			CZ 20003982 A3	14-02-2001
			DK 1073656 T3	16-01-2006
			EE 200000626 A	15-04-2002
			EE 200000664 A	15-04-2002
			EP 1073656 A1	07-02-2001
			EP 1073657 A1	07-02-2001
			HK 1036981 A1	27-05-2005
			HK 1036984 A1	29-04-2005
			HU 0102313 A2	28-12-2001
			HU 0102425 A2	28-11-2001
			ID 27530 A	12-04-2001
			ID 26819 A	15-02-2001
			JP 2002513024 T	08-05-2002
			JP 3692034 B2	07-09-2005
			JP 2002513025 T	08-05-2002
			NO 20005450 A	22-12-2000
			NO 20005451 A	27-12-2000
			NZ 507638 A	31-10-2003
			NZ 507639 A	30-01-2004
			PL 343797 A1	10-09-2001
			PL 343801 A1	10-09-2001
			RU 2238271 C2	20-10-2004
			RU 2235725 C2	10-09-2004
			WO 9955705 A1	04-11-1999
			SK 14912000 A3	11-06-2001
			SK 14922000 A3	11-06-2001
			TR 200003149 T2	21-03-2001

INTERNATIONAL SEARCH REPORT

International application No
PCT/IB2005/003758

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9955706	A	TR 200003176 T2	21-03-2001
		TR 200102612 T2	21-06-2002
		TR 200102728 T2	21-06-2002
		TW 490466 B	11-06-2002
		UA 67769 C2	15-05-2002
		UA 66846 C2	15-05-2002
		US 6313136 B1	06-11-2001
		US 6313137 B1	06-11-2001
		ZA 200005796 A	18-01-2002
